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General introduction
This thesis explores the value of pulsed dye laser in the treatment of inflammatory 
skin diseases, in particular psoriasis and cutaneous discoid lupus erythematosus 
(CDLE). This work is inspired by the well established effect in vascular lesions and the 
evidence of involvement of the microvasculature in inflammatory dermatoses. In this 
introduction we will highlight the current knowledge on laser therapy, describe the 
clinical aspects of these diseases and finally we will define the aims of this thesis.
1.1 Laser therapy
1.1.1 History
The term LASER is an acronym for Light Amplification by Stimulated Emission of 
Radiation. The concept of stimulated light emission was introduced by Einstein in 
1917.1 He proposed that a photon of electromagnetic energy is able to stimulate 
the emission of another identical photon from atoms or molecules that are in an 
excited state. Based on this theory, Maiman developed more than forty years later, in 
1960, the first laser by using a ruby crystal to produce red light with a wavelength of 
694 nm.2 In 1963, Goldman became the first physician to utilize a laser on humans, 
initiating dermatologic application of laser technology.3,4 He applied the ruby laser for 
a variety of cutaneous pathologies. During the next two decades the development of 
the argon and carbon dioxide (CO2) lasers soon followed and served as the focus of 
cutaneous laser research.5,6 The argon laser emits blue-green light (wavelengths 488 
and 514 nm) and was initially used to treat congenital vascular lesions. Although this 
treatment showed an effective lightning in most hemangiomas and port-wine-stains, 
hypertrophic scar formation was frequently seen as a side effect.5,7,8 The CO2 laser, 
emitting infrared light at 10,600 nm, was used for tissue vaporization and destruction 
of different epidermal and dermal lesions.5,9 The prolonged tissue exposure to laser 
energy resulted in excessive thermal injury of the skin, what unfortunately often led 
to side effects as hypertrophic scarring and pigmentary changes. Anderson en Parrish 
brought a revolution to the cutaneous laser surgery by introducing the theory of 
selective photothermolysis in 1983.10 This theory describes specific destruction of a 
target in the skin with minimal thermal injury, providing a more selective approach 
with less collateral damage. In the years following this discovery till now, greater 
understanding of the complex laser-tissue interaction in combination with extensive 
advances in laser technology have brought cutaneous laser surgery to the point that 
it is now: the golden standard for the treatment of many congenital and acquired 
conditions.5, 11
14
1.1.2 Physical principles5,12
For a detailed review on physical principles the reader is referred to a review by 
Ratz et al.5 In the electromagnetic spectrum (figure 1), light is one portion that 
exhibits properties of photons and waves. Photons of light are like small packages, 
each having a specific wavelength that serves as the “stuff” inside the package. 
The wavelength is responsible for the colour of visible light. Wavelengths of visible 
light range from approximately 400 nm (violet) to approximately 750 nm (red). 
Ultraviolet light has much shorter (10-400 nm) wavelengths, whereas infrared 
light has much longer (750-1,000,000+ nm) wavelengths. Regardless of colour 
or wavelength, the speed of light is constant at 299,792,458 m/s. This speed is 
constant per unit of time, so the frequency (the number of wavelengths within 
a unit of time) will be high for short wavelengths and low for long wavelengths. 
Each atom or molecule has a natural tendency to exist in its natural or resting 
state, with its outer orbiting electron in a stable position. By absorbing a photon 
of energy, the outer orbiting electron is moved into the next orbital level, which 
is an unstable condition. Its natural tendency will be to drop back to its normal or 
resting state and releasing a characteristic photon of energy, called spontaneous 
emission. When many atoms or molecules undergo spontaneous decay, the 
emission will be out of phase with one another. However, if a photon of enough 
energy stimulates an electron in its excited state, that photon will cause orbital 
decay of the electron, sending the electron back to its resting state, resulting in 
Chapter 1
Figure 1. The electromagnetic spectrum.
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the emission of a second photon identical to the incident photon. So, two photons 
of equal wavelength (colour) are released from the atom, and those two photons 
are travelling in the same direction and are in phase both spacially and temporally. 
This process, called stimulated emission, is the first necessary element in the 
production of laser light (figure 2). Normally, atoms or molecules contain a much 
greater number of particles in their resting state. Pumping enough energy into 
the system, more atoms or molecules are transformed into their excited states. 
This change, called population inversion, is necessary for the production of laser 
light. If energy is still being pumped into the system, after population inversion has 
occurred, the stimulated emission of in-phase photons will result in their impact 
on other excited-state electrons, which results in additional in-phase photons that 
will do the same thing, namely produce more in-phase photons. In the optical 
resonator of the laser, this chain-reaction “mass production” of in-phase photons 
is further magnified, resulting in light amplification (figure 3).
A B C
D E
Figure 2. Resting state of atom or molecule (2A), after absorbing a photon of energy the outer 
orbiting electron is moved to the next level (2B); without further power the unstable electron 
falls back releasing energy (2C); further absorption energy results in stimulation of excited-
state atom or molecule (2D). Stimulation of the excited-state atom or molecule results in 
falling back of the stimulated electron and emission of two identical photons travelling in the 
same direction (2E).
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1.1.3 Laser design and properties of laser light12
Basically the design of every laser is the same (figure 3). It consists of three basic 
parts:
1.   An optical cavity or resonator.
2.   An active medium with a suitable set of energy level to support laser action.
3.   A source of pumping energy.
Ad 1. The optical cavity, also called (optical) resonator, chamber or laser cavity, can 
be thought of as an elongated box with a “hole” in one end. At the end of the box 
is a fully reflective mirror and at the opposite end a partially reflective mirror, which 
allows for transmission of only a very small amount of light.
Ad 2. The optical cavity contains a medium which can be solid (crystal), liquid 
(rhodamine dye dissolved in organic solvent), a gas or a mixture of gases (argon, 
Chapter 1
Figure 3. Basic laser Construction (A), external power is introduced to the laser (B), production 
of laser light (C), laser light entering the laser delivery system (D).
A
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D
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carbon dioxide, copper vapour, xenon chloride etc). The medium becomes an active 
medium when it is energized into its excited state by a power source. Lasers are 
named according to their medium.
Ad 3. The pumping energy can be derived from different sources including electricity, 
radio-frequency enhancement, light, chemical reaction and mechanical power. Most 
medical lasers are pumped by electrical or optical energy or by radio-frequency 
enhancement.
When external power is introduced to the laser, atoms are elevated to their excited 
state and a population inversion occurs. The resulting photons released are all 
identical and are reflected back and forth between the mirrors at each end of the 
optical cavity. Continued absorption of energy results in further stimulated emission 
and ultimately in light amplification and the production of laser light. This light enters 
the laser delivery system, which for most lasers is quartz fibre optics.
Laser light has some key properties that distinguish it from other light sources and 
which are the basis for the therapeutic application. These properties are:
Monochromacity: The specific wavelength of laser light influences the distance it 
can penetrate into the tissue. The depth of the penetration generally increases with 
increasing wavelength within the spectrum of visible light
Coherence: The waves of light are in phase with each other in both time and space. 
The light emitted from a laser is in the same direction and in the same phase.
Collimation: A laser creates a collimated beam by reflecting the light between the two 
mirrors in the optical cavity, that allows the exit of parallel waves only. The tendency 
toward divergence is low because the waves of light are parallel to each other.
High power: The amplification process within the optical cavity produces a high 
power density. Some lasers are capable of the continuous discharge of light, called 
continuous wave (CW), whereas others seem to build up power before releasing their 
pulse of relatively high power (pulsed lasers). Duration and power of the pulse can be 
varied. The output of continuous wave lasers is measured as power in watts (W), for 
pulsed lasers output is measured as energy in joules (J) taking the pulse duration in 
account. Irradiance, the power density of a laser beam, refers to laser power per unit 
area and takes the spot size (area of laser beam= π.r2) in account (W/cm2). Energy 
density or fluence is defined as the irradiance multiplied by exposure time (J/cm2). 
Fluence and irradiance are directly proportional to each other:
Fluence (J/cm2) = irradiance (W/cm2) x exposure time (s)
1.1.4 Laser-tissue interaction5,13,14
After a beam of light strikes the skin, 4-7% is reflected because of the difference 
in the refractive indices of air and stratum corneum. The remaining 93-96% enters 
the skin, where it is scattered, transmitted or absorbed. Scattering occurs when 
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particles within the skin spread the incoming beam of light in all directions, limiting 
its depth of penetration. Light is transmitted when it passes through the tissue 
unaltered. In general, only when light is absorbed, tissue effects can occur: the 
photon surrenders its energy to an absorbing molecule, called chromophore. The 
amount of absorption is determined by the chromophore present in the skin and 
whether a wavelength that corresponds to the absorptive characteristics of that 
chromophore is used. The principal endogenous chromophores of the skin are 
water, melanin and haemoglobin, whereas tattoo ink is an example of an exogenous 
chromophore. Once laser energy has been absorbed in the skin photochemical, 
photomechanical or photothermal effects may occur; destruction of the target 
results from the conversion of absorbed energy into heat. Photochemical effects 
result from the native or photo sensitizer related reactions, de facto the principle 
of photodynamic therapy. Photomechanical effects result from acoustic waves 
induced by the extremely rapid thermal expansion, causing destruction of the 
absorbing tissue. Photothermal effects occur when a chromophore absorbs the 
corresponding wavelength of energy. 
1.1.5 Selective photothermolysis5,10,14,15
In dermatology, the ultimate aim of the use of lasers is to direct energy selectively at 
a specific chromophore, without collateral damage to the adjacent tissues. This is the 
principle of selective photothermolysis. 
In order to reach selectivity, the beam of light produced by the laser must have a 
wavelength preferentially absorbed by the targeted chromophore in the lesion, the 
fluence must be sufficiently high to generate enough energy to thermally alter the 
target tissue and the pulse duration must be shorter than the thermal relaxation 
time (TRT) of the chromophore to prevent spread of thermal energy beyond the 
targeted chromophore. The TRT is the time required by the chromophore to cool 
down to half of its peak temperature after laser irradiation and is proportional to 
the square of the size of the chromophore. In general, small objects have a shorter 
TRT than large ones; melanosomes of 0.5-1.0 μm cool faster than capillaries 
measuring 10-100 μm. If the pulse width exceeds or equals the TRT, the heat 
diffusion to surrounding tissues leads to unnecessary thermal damage. Finally, the 
energy delivered to the chromophore must by high enough to destroy it, within 
the pulse duration. So, by fine-tuning the wavelength, the pulse duration and the 
fluence, a laser can be tailored to provide selective damage to the lesions without 
non specific thermal damage to the skin.
1.1.6 Vascular lasers 5,16
Vascular laser systems target intravascular oxyhemoglobin. The three primary 
absorption peaks for oxyhaemoglobin are within the visible range of the 
Chapter 1
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electromagnetic spectrum: 418, 542 and 577 nm (figure 4). The dominant 
absorption peak is 418 nm, but this wavelength only penetrates into the dermal-
epidermal junction (100 μm), which restricts the use of a laser with this wavelength 
for cutaneous vascular lesions. Lasers that have been used to treat vascular lesions 
include argon laser (488/514 nm), argon pumped tunable dye (APTD) (577/585 
nm), potassium titanyl phosphate (KTP) (532 nm), krypton (568 nm), copper 
vapour/bromide (578 nm), pulsed dye laser (PDL) (585/590/595/600 nm), long 
pulsed alexandite laser (755 nm), diode laser (800 nm), neodymium-doped yttrium 
aluminium garnet (Nd:YAG) (532/1064 nm).
The argon laser produces nonspecific thermal injury resulting from exposure 
intervals exceeding the thermal relaxation time of the vessels, so increasing the risk 
of scarring and dyspigmentation. The APTD, krypton, copper vapour/bromide and 
KTP lasers are continuous wave (CW) that can be mechanically shuttered to deliver 
pulses as short as 20 ns called quasi-CW. Unfortunately this quasi-CW nature is often 
associated with higher incidences of hypertrophic scarring and textural changes. The 
KTP laser uses a Nd:YAG crystal (1064 nm) to produce light that is passed through 
a KTP crystal that frequency doubles the wavelength to 532 nm. Good results have 
Figure 4. Absorption spectra. Note the heterogeneous absorption spectra of chromophores. 
(modified from Acland KM and Barlow RJ. Lasers for the dermatologist. Br J Dermatol 2000 
Aug;143(2):244-55)
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been reported by several investigators, after treatment of facial teleangiectasias 
with this device. Compared with longer wavelength vascular-specific lasers, potential 
limitations of the 532 nm wavelength include decreased tissue penetration of its 
shorter wavelength resulting in diminished absorption by deeper vessels. In addition, 
the 532 nm wavelength is more avidly absorbed by melanin than the 585/595 nm 
wavelength of the PDL, thereby limiting its use for patients with darker skin types. 
The flashlamp-pumped PDL was the first laser developed specifically for the 
treatment of vascular lesions based on the principles of selective photothermolysis. 
It uses a high power flashlamp to energize an organic dye (rhodamine) and produce 
a true pulse of yellow light. Although original investigators used a 577 nm system, 
the wavelength was modified to 585 nm and more later to 595 nm and 600 nm, 
to effect a deeper tissue penetration, while maintaining vascular specificity. Also 
the pulse duration has been prolonged from 0.45 ms up to 40 ms, so vessels could 
be heated more slowly, producing less profound and shorter lasting purpura. Also, 
dynamic cooling devices were incorporated to reduce discomfort during treatment 
and postoperative occurrence of epidermal damage and pigmentary change. 
The pulsed dye laser is considered to be the treatment of choice for many vascular 
lesions.11 The efficacy of PDL in vascular lesions has been thoroughly investigated. 
Its application has been expanded to treatment of other skin conditions such as 
inflammatory skin diseases, currently addressed in this thesis. The efficacy and 
position of the PDL in these inflammatory skin diseases has only sparsely been 
explored, and is addressed in this thesis.
Chapter 1
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1.2 Psoriasis
1.2.1 Epidemiology
Psoriasis is a chronic relapsing non-infectious inflammatory skin disorder, which 
affects approximately 1-3 % of the Caucasian population.17,18 The highest prevalence 
is seen in European and North American Caucasians. The disease is uncommon in 
Afro-Americans and almost non-existent in Native Americans.18 Man and women are 
equally affected.19 The disease may occur at any age although two peak incidences 
have been reported: a peak between 16 and 22 years and a later one at 57-60 years, 
the late onset type.20 
Genetic disposition seems to play an important role in the susceptibility to develop 
psoriasis. Population studies have shown that the incidence is greater in first and 
second degree relatives of psoriasis patients than in the general population. There 
is evidence that multiple genes are involved and this had led to the identification of 
different psoriasis-susceptibility loci.21,22
1.2.2 Clinical presentation
Psoriasis is a skin disease with a variable morphology, severity, distribution and 
course.
The commonest type of psoriasis is chronic plaque psoriasis (psoriasis vulgaris), which 
accounts for approximately 90 % of all cases. It is characterized by often symmetrically 
distributed, sharply demarcated, erythematosquamous plaques of varying size with 
predilection sites on the dorsal sites of the elbows, knees and on the scalp and sacral 
region. The scales of these lesions are typically silvery white and scratching these 
looks like scratching on a wax candle (“signe de tache de bougie”).23
Guttate psoriasis (psoriasis guttata) is the acute onset of droplet-like lesions 
disseminated over the body. Classically, it occurs after an acute group B haemolytic 
streptococcal infection or viral infection of the pharynx or tonsillitis and often clears 
in a few weeks to months.23
Various forms of pustular psoriasis have been described. Generalized pustular psoriasis 
(Von Zumbusch psoriasis) is characterized by disseminated deep-red erythematous 
areas and pustules, which may merge to extensive lakes of pus. Localized forms 
include palmoplantar pustulosis (morbus Andrews-Barber) and acrodermatitis 
continua of Hallopeau, consisting of yellow-brown, sterile pustules on a background 
of erythema and scaling affecting the palms and/or soles.23
Both pustular and the erythematosquamous forms may progress to psoriatic 
erythroderma, which can lead to hypothermia, hypoalbuminaemia and high output 
cardiac failure eventually rendering it as a possible life-threatening condition.
Extracutaneous manifestations of psoriasis are nail psoriasis (psoriasis unguium) and 
psoriatic arthritis (psoriasis arthropatica). Nail involvement is present in 25-50% of all 
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types of psoriasis and is more frequently seen with psoriatic arthropathy. The most 
common changes seen in nails are pitting, discoloration (oil drop phenomenon), 
subungual hyperkeratosis and onycholysis. Psoriatic arthritis occurs in about 5-10% 
of patients with psoriasis.
The studies in this thesis have been focused on plaque psoriasis, especially solitary 
recalcitrant lesions. 
1.2.3 Clinical course and triggering factors
The course of psoriasis is unpredictable, but is usually chronic with exacerbations and 
remissions. It is a multifactorial disease caused by the interaction between genes and 
environmental triggering factors. Genetic predisposition is apparent and has been 
confirmed in twin studies, which have been reviewed in 1997.24
Triggering factors have been reported to play a role in the initiation of the disease 
process and exacerbation of pre-existing disease. These are trauma (Koebner 
phenomenon),25 infections (particular streptococcal infections of the upper respiratory 
tract), drugs (β-blokkers, lithium, anti-malarials, non-steroidal anti-inflammatory 
agents),26 psychogenic stress,27 increased alcohol consumption, obesity, smoking 
and HIV.26,28 Repeated traumata at friction sites or combination of itching conditions 
(neurodermatitis or prurigo) with psoriasis can be a trigger yielding into solitary 
recalcitrant lesions. 
Figure 5. Clinical picture of recalcitrant plaque psoriasis localized on the elbow.
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Figure 6. Classical histopathological picture of psoriasis with the characteristic epidermal 
and inflammatory abnormalities; note the robust dermal papillae with the increased 
microvasculature and the thinning of the suprapapillary plate.
1.2.4 Histopathology23
In general, psoriasis has three main histopathologic features:
1.   Epidermal hyperplasia with epidermal thickening.
2.   An inflammatory infiltrate of mainly T-cells, predominantly intra-dermal.
3.   Dilated, elongated and increased prominent superficial capillaries in the dermis.
The histopathologic findings can vary with the age of the lesions.29
1.2.5 Treatments of psoriasis
A spectrum of treatments is available for the management of patients with psoriasis. 
The majority of patients is treated with a topical treatment such as vitamin D,30 
corticosteroids,31-33 or calcineurin inhibitors.34 Classical topical treatments such as 
dithranol35 and tar36 are provided at day care centres and these options may be 
indicated as second line topicals. Photo(chemo)therapy,37 classical systemic treatments 
such as methotrexate,41,42 fumarates,38-40 retinoids43 and cyclosporine44 are indicated 
if the condition is too wide spread and or in situations that topical treatments are 
not effective enough or not practical. The next level of treatment are biologics (anti-
TNF treatments and anti-p40 IL12/23) for those patients who cannot be controlled 
adequately on the previously mentioned options.45,46 One manifestation represents 
major difficulties in the management of psoriasis: solitary chronic recalcitrant lesions. 
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These lesions remain after intensified topical and systemic treatment and can be the 
reason for prolonged treatment and high cumulative toxicity resulting from dose-
increments of treatments. Solitary recalcitrant plaques are an unmet need in the 
management of psoriasis.
Most treatments focus on the inflammatory changes and/or epidermal changes 
in psoriasis. An option which has not been explored sufficiently in the past is the 
endothelial changes in psoriasis as a potential anti-psoriatic target. Therapies 
which focus on the alteration in the capillaries have been neglected as a possible 
therapeutic target, although several reports mentioned an increase in the dermal 
papillary vasculature as one of the earliest observable changes in a new psoriatic 
lesion.47-50 The clinical improvement during treatment is preceded by micro-vascular 
improvement, indicating that the expanded superficial micro-vasculature bed of 
psoriatic skin is an essential component, which maintains clinical lesions. Due to these 
observations, the hypothesis is, that selective destruction of the dilated papillary 
vessels in psoriasis by selective photothermolysis, may reduce the transmigration of 
inflammatory cells, and so clearing psoriasis plaques. Several studies reported partial 
and total clearance of psoriasis after PDL treatment.51-57 In this thesis the efficacy and 
safety of PDL treatment in recalcitrant plaque psoriasis is studied and compared and 
contrasted with established therapy.
Figure 7. Recalcitrant plaque psoriasis devided in four parts; each consecutive part was treated 
once with fluences 5.5, 6.5, 7.5 and 8.5 J/cm2, using the same spot size. Note the marked 
improvement for the section treated with 8.5 J/cm2.
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1.3 Chronic discoid lupus erythematosus
1.3.1 Epidemiology58-62
Chronic discoid lupus erythematosus (CDLE), is one of the three major forms of 
lupus erythematosus (LE). This is a spectrum of diseases with variation in course and 
prognosis. There is an overlap in clinical, histological and laboratory findings which 
may change during the course of the disease making the distinctions difficult. The 
other two major forms are subacute cutaneous lupus erythematosus (SCLE) and 
systemic lupus erythematosus (SLE).
CDLE is the most common form of cutaneous lupus. Women are more affected than 
men with a ratio ranging from 2:1 to 4:1. The risk of a patient with CDLE developing 
overt SLE is between 1.3 and 5%. The disease typically affects young patients, with 
an onset between 20 and 40 years. It has been proposed that genetic factors and 
somatic mutations are implicated in the pathogenesis of the disease
1.3.2 Clinical presentation58-62
Each CDLE lesion is characterized by well defined, erythematous scaly patches, 
which tend to heal with scarring, atrophy and pigmentary changes. The lesions start 
with persistent indurated erythematous papules and plaques, centrally covered 
by a firmly adherent white scale. If the scale is removed, hyperkeratotic spicules 
can been seen, representing follicular plugs (carpet tack sign). While evolving, the 
periphery is typically raised and erythematous, while the centre gradually becomes 
atrophic. There are pigmentary changes as well, showing hypo- or depigmentation 
in black skin, and hyperpigmentation and teleangiectases in white skin. The face is 
most commonly affected, and the scalp, ears, nose, arms, legs and trunk to a lesser 
extent. Alopecia occurs in the scalp lesions in approximately one-third of patients 
and is usually permanent. CDLE can be either localized or disseminated. The course 
of CDLE is difficult to predict. Each patient with newly diagnosed CDLE should be 
evaluated for signs of SLE. If these are negative, then one can diagnose CDLE as LE 
limited to the skin. The onset of lesions may be precipitated by a variety of factors, 
including trauma, mental stress, sunburn, infection, exposure to cold and pregnancy. 
Occasionally, drugs may precipitate lesions of CDLE. Once lesions have developed, 
exacerbations may be triggered by a variety of factors, like sun exposure, cold, 
hormonal changes and mental stress.
1.3.3 Histopathology59,60
The epidermis is usually atrophic with follicular plugging. The basilar keratinocytes 
show vacuolar degeneration, while the microscopic basement membrane zone is 
more prominent and thickened. In the dermis there are lymphocytic infiltrates around 
the vessels and adnexal structures, and scattered diffusely. Perifollicular infiltrates are 
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especially common. In addition, mucin is common, as are telangiectases. Collagen 
and elastic fibres are both damaged. The infiltrate can extend to the subcutaneous 
fat, where typically there is both lobar and septal involvement. Immunoglobulins IgG, 
IgA, IgM and complement can be observed in approximately 80% of the patients at 
the dermal-epidermal junction in skin lesions present for six weeks or more. 
1.3.4 Treatment of CDLE
CDLE can be treated with different therapies, as monotherapy or in combination 
therapy. In general topical agents, systemic medication and physical/surgical therapies 
are treatment options.
Topical therapies commonly used for CDLE includes high potent corticosteroids,62-64
sunscreens65 and calcineurin inhibitors,76,77 whereas systemic therapies includes 
antimalarial agents66-67, glucocorticosteroids,58,59 retinoids,68,69 dapson,70 methotrexate,71
thalidomide,72 immunoglobulins,73 azathioprine,74 cyclophosphamid,75 biologicals,78,79 
cyclosporine,80 immunoglobulins,81 mycophenolate mofetil,82 rituximab83 and anti-
TNFα agents.84
Physical and surgical therapies are indicated, when the topical and systemic treatments 
lack efficacy or show/predict (serious) adverse events. Physical and surgical therapies 
includes cryotherapy,58,59dermabrasion58,59 and laser treatment,85-90 preferentially 
with the pulsed dye laser. The development of laser therapy for recalcitrant lesions 
in CDLE may provide an important innovation for better care for these patients.
Figure 8. Histology of chronic discoid lupus erythematosus.
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Figure 9. CDLE lesion on the right cheek before PDL treatment (A) Almost total clearance of 
CDLE lesion right cheek after laser treatment (B).
Concerning the role of the PDL in the modulation of the inflammatory response of 
CDLE, it has been observed that the endothelial cell activation plays an important role 
in the pathogenesis of lupus.89,90 This role could be due to the fact that higher levels 
of adhesion molecules on the surface of the endothelial cell, such as E-selectine, 
are correlated with active disease in LE patients. The hypothesis is that the selective 
destruction or coagulation leads to a modulation of the inflammatory network.89,90
In order to find out whether a new treatment provides a significant innovation, 
objective and reproducible disease assessment is needed. So, to monitor the clinical 
effects of pulsed dye laser therapy, the objective determination of the skin lesion 
status is necessary. The cutaneous lupus erythematosus disease area and severity 
index (CLASI)91 is an important instrument for disease severity assessment. In brief, 
this instrument has separate scores for activity and damage of CDLE lesions at 13 
anatomic sites. It is an extensive instrument and not focused on one single lesion.
28
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1.4 Aims of this thesis
In chronic therapy-resistant recalcitrant lesions of inflammatory skin diseases, 
the clinician is faced with an important unmet need for effective treatment. The 
involvement of the microvasculature in the pathogenesis of psoriasis and CDLE 
provides a potential new therapeutic target. So far, a selective therapeutic targeting 
of microvasculature has not been systematically investigated in these diseases. 
Vascular laser technology provides a challenging tool to explore this promising 
option in inflammatory conditions, based on the experience of laser intervention 
with vascular conditions.
Overall aim:
To explore the value of pulsed dye laser in the treatment of inflammatory skin 
diseases, inspired by the well established effect in vascular lesions and the evidence 
of involvement of the microvasculature in inflammatory dermatoses.
Aim 1:
To investigate the efficacy of a vascular laser in spider naevi.
Aim 2: 
To explore the potential value of pulsed dye laser in solitary recalcitrant lesions of 
plaque psoriasis and CDLE.
Aim 3:
To position pulsed dye laser therapy in inflammatory skin diseases based on a 
systematic literature review.
In the general discussion the value of pulsed dye laser treatment in inflammatory 
skin diseases will be discussed and treatment recommendations will be provided.
30
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ABSTRACT
Objective: To assess the clinical efficacy and safety of potassium titanyl phosphate (KTP) 
laser treatment and electrocoagulation (EC) for the treatment of spider nevi (SN).
Method: A randomized single-blind intrapatient comparison study was performed. A 
blinded observer and patients reported the clinical treatment outcome and pain on 
a visual analogue scale (0–10). Side effects were noted if present.
Results: Mean physician-rated clinical efficacy scores ± standard error of the mean 
were 7.7 ± 0.7 for KTP laser and 6.2 ± 0.9 for EC treatment (p =.05). Patient-rated 
mean clinical efficacy of KTP laser was 8.3 ± 0.6 and of EC was 7.3 ± 0.7 (p =.09). 
Stratification for potential confounding bias, such as location of SN, central bulging 
vein, and diameter (p =.25) of the treated SN did not reveal any statistically significant 
differences between the treatments. Treatment with KTP or EC did not result in 
scarring or pigmentary changes. Pain was reported for KTP treatment (3.1 ± 0.4) and 
EC (6.4 ± 0.7) (p <.05).
Conclusion: Clinical efficacy of KTP laser and EC for SN is comparable, although there 
is a tendency toward an advantage in favor of the KTP laser. KTP laser treatment was 
less painful.
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A comparative study of pulsed 532-nm potassium 
titanyl phosphate laser and electrocoagulation in 
the treatment of spider nevi
INTRODuCTION
Spider nevi (SN), also known as spider angiomas, vascular spiders, or naevus araneus, 
are small conglomerates of dermal capillaries consisting of a central arteriole with 
radiating thin vessels. The name derives from the central part of a SN, which looks 
like a spider’s body, and the radiating vessels, which resemble multiple spider legs. 
Redisch and Pelzer classified them based on clinical appearance as one of the four 
types of telangiectasias.1 All forms of telangiectasias are thought to occur through 
the release or activation of vasoactive substances under a multitude of conditions, 
including anoxia, hormones, chemicals, infections, and physical factors, with resulting 
capillary or venular neogenesis.2 SN are benign and may be indicative of underlying 
systemic disease in extensive cases, although most lesions are unrelated to internal 
disease.3,4 Lesions developing during pregnancy or due to oral contraceptives usually 
resolve spontaneously after delivery or discontinuation of medication. SN are 
observed in 10% to 15% of healthy adults and young children.5 Although occurring at 
any age, two age peaks have been demonstrated: in childhood and early middle age. 
The face, neck, upper part of the trunk, and arms are the most frequently involved 
regions.
Whereas the psychological effect of port wine stains is widely recognized, the 
psychological distress caused by superficial vascular lesions at visible body sites 
is often underestimated.6,7 Because the treatment of SN is more a cosmetic than 
a medical treatment, the treatment modalities should be effective with no side 
effects such as pigmentary changes and scarring. Traditionally, SN were treated using 
electrosurgery (electrocoagulation, EC). A needle-like (pin shaped) tip is applied 
to the central point of the SN (on the so-called feeding vessel) and destroys the 
feeding vessel using cold point cautery or electrodesiccation.8 With this procedure, 
the radiating vessels disappear, avoiding collateral damage to the surrounding skin. 
Arndt first reported laser therapy for SN in 1982.9 Thirty-one patients with small 
vascular lesions were treated with the argon laser, and good to excellent results were 
observed in patients with SN. The argon laser was the original treatment of choice 
for vascular lesions, but the continuous nature of the beam produced nonspecific 
thermal injury in adjacent tissue, increasing the risk of scarring and permanent 
pigmentary changes. The development of more effective pulsed lasers such as the 
pulsed dye laser (PDL), pulsed potassium titanyl phosphate (KTP) laser, and pulsed 
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infrared laser greatly improved the efficacy and decreased the side effects of vascular 
lasers. Therefore, KTP lasers and PDL lasers are commonly used treatment modalities 
for SN. In daily practice, EC is easily available and can be instantly performed in 
outpatient departments. Vascular lasers, on the other hand, are less accessible than 
EC devices, so the use of lasers for SN is more limited.
To our knowledge, no controlled or comparative studies have been performed to 
assess the effectiveness of traditional EC with KTP laser treatment. We therefore 
designed a comparative clinical study to compare the efficacy and safety of both 
treatments in daily practice.
MATERIAL AND METHODS
Patients
Twelve patients with at least two SN on the face or chest who visited the Department 
of Dermatology at the Jeroen Bosch Hospital, ’s Hertogenbosch, The Netherlands, 
over a 6-month period were asked to participate in the study. Exclusion criteria were 
younger than 18 and tanned or Fitzpatrick skin type IV or more. Written informed 
consent to participate in the study was obtained from all patients.
Chapter 2
Table 1A. Patient characteristics: potassium titanyl phosphate–treated spider nevi.
* Visual analogue scale (VAS) range 0–10. F, female; M, male.
Patient 
Number
Sex/
Age Location Bulging
Diameter 
(mm)
Clinical Effect
(VAS* Score) 
According to 
Patient
Clinical Effect
(VAS* Score) 
According to 
Physician
Pain (VAS 
Score*)
1 F/49 Face Yes 9 9.0 7.4 2.4
2 F/62 Face No 4 2.7 3.8 2.0
3 F/57 Face No 10 9.2 8.1 1.4
4 F/48 Face No 3 8.6 9.0 2.8
5 F/46 Face Yes 5 9.2 8.8 5.7
6 F/66 Face No 4 8.0 7.1 1.9
7 F/64 Face No 3 8.1 6.6 2.2
8 F/35 Face No 6 8.9 9.1 3.1
9 F/65 Face Yes 4 5.3 3.0 2.7
10 F/37 Face No 5 10 9.1 5.3
11 F/37 Chest No 5 10 10 4.0
12 M/26 Face No 5 10 10 3.6
Mean 49 5.3 8.3 7.7 3.1
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Study design
At the initial visit, two SN were selected for treatment. If patients had more than two 
SN, the two most similar in size and appearance were chosen. Randomly, one SN was 
treated with EC (Hyfrecator, Con Med Corp., Centennial, CO; 2,000 electrosurgical 
units, position 12) and the other with the KTP laser (VersaPulse VPW, Coherent, Palo 
Alto, CA), a KTP frequency-doubled neodymium-doped yttrium aluminum garnet 
(Nd:YAG) laser. A sapphire-chilled contact cooling tip is attached to the handpiece, 
which cools the epidermal surface before and during the treatment. Treatment 
parameters were two passes at the feeding vessel with a 4 mm spot size, a fluence 
of 18 J/cm2, a frequency of 1.5 Hz, and a pulse duration of 30 ms. The cooling device 
was set at 3 °C. A water-soluble refractive gel (Aquasonic Clear, Parker Laboratory, 
Fairfield, NY) was applied before laser treatment was initiated. The maximal diameter 
of the lesions (mm) was measured. The location of the lesions and the presence 
of a central bulging vein were reported. All lesions were documented using digital 
photography before treatment.
After treatment, all patients were instructed to avoid ultraviolet light exposure and 
to use a sunblock (SPF 50) for the entire follow-up period of 6 weeks. Immediately 
after treatment, the severity of perceived pain was scored on a visual analogue scale 
(VAS) ranging from 0 to 10 (0 = no pain, 10 = maximal perceived pain). Adverse events 
were recorded.
Table 1B. Patient characteristics: electrocoagulation-treated spider nevi.
* Visual analogue scale (VAS) range 0–10. F, female; M, male.
Patient 
Number
Sex/
Age Location Bulging
Diameter 
(mm)
Clinical Effect
(VAS* Score) 
According to 
Patient
Clinical Effect
(VAS* Score) 
According to 
Physician
Pain (VAS 
Score*)
1 F/49 Face No 4 5.4 2.4 6.7
2 F/62 Face No 4 2.3 0 3.0
3 F/57 Chest No 8 9.2 9.1 4.6
4 F/48 Face Yes 3 8.0 7.8 5.1
5 F/46 Face Yes 4 8.7 8.2 8.0
6 F/66 Face No 4 4.0 5.2 5.8
7 F/64 Face No 4 5.7 3.0 7.6
8 F/35 Chest No 7 8.7 5.7 7.2
9 F/65 Face Yes 5 7.8 6.0 2.2
10 F/37 Face No 5 8.2 8.0 9.1
11 F/37 Chest No 5 10 10 9.7
12 M/26 Face No 4 10 9.5 7.3
Mean 49 4.7 7.3 6.2 6.4
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Clinical assessments
A blinded independent observer assessed the treatment outcome of all patients at 
the end of a 6-week follow-up period. The observer did not know which treatment 
(KTP or EC) had been given. SN were compared to baseline photography on a VAS 
ranging from 0 (no improvement at all) to 10 (total disappearance of the SN). The 
patients performed the same assessment using an identical VAS. Side effects were 
noted if present (e.g., hypopigmentation, hyperpigmentation, and scar formation).
Statistical analysis
Two-tailed paired t-tests were performed using Statistica statistical software version 
6.0 (Statsoft, Tulsa, OK) to compare the difference between pre- and post-treatment 
VAS scores. A statistical significant difference was apparent if p <.05. 
RESuLTS
Patient characteristics
Twelve patients (1 male, 11 female) with mean age ± standard error of the mean of 
49.3 ± 3.9 were included. Patient characteristics are depicted in tables 1A and 1B.
KTP versus EC: patient assessments
Patients rated the clinical efficacy of KTP and EC treatment of their SN on a VAS of 0 to 
10. The mean patient assessment of KTP treatment was 8.3 ± 0.6, whereas the mean 
score was 7.3 ± 0.7 for treatment of SN with EC. This difference was not statistically 
significant but showed a tendency toward significance in favor of the KTP-treated SN 
(p =.09) (figure 1A).
Figure 1. Clinical efficacy, assessed by patients (A)
and physicians (B), and pain perception 
of potassium titanyl phosphate (KTP) and 
electrocoagulation (EC) treatment (C). Scores 
are depicted on a scale from 0 (absent) to 10 
(maximal score) as means ± standard errors of 
the mean. * Statistically significant.
A                  Patient assessment B                Physician assessment
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KTP versus EC: physician assessment
The mean physician VAS scores were 7.7 ± 0.7 for KTP and 6.2 ± 0.9 for EC. Similar to 
the patient derived scores, this difference was borderline statistically significant in 
favor of treatment of SN with KTP (p =.05) (figure 1B).
Confounders: location, bulging, and diameter of SN
Stratification for potential confounding bias, such as location of SN, central bulging 
vein, and diameter of the treated SN did not reveal any significant results. Patients had 
at least two SN, 20 (83%) were located in the face and 4 (17%) on the chest (p >.05).
Six SN had a central bulging vein; three of those were treated with KTP and three with 
EC (p >.05). Diameters of the lesions before treatment were comparable: 5.3 ± 0.6
for the KTP-treated SN and 4.7 ± 0.4mm for the EC-treated SN (p =.25). The three 
mentioned variables did not correlate to the degree of response to treatment with 
KTP or EC (all p >.05; data not shown).
Side effects of treatments
Treatment with KTP or EC did not result in hypopigmentation, hyperpigmentation, or 
scar formation in the investigated cases. Pain was reported as the only adverse event 
(mean: KTP, 3.1 ± 0.4; EC, 6.4 ± 0.7). This result was statistically significant in favor of 
KTP laser treatment (figure 1C).
DISCuSSION
Because EC and KTP laser treatment are both commonly used methods to treat SN, a 
randomized single-blind intrapatient comparative study was performed in which the 
efficacy and safety of these treatments were assessed.
The data from the present study demonstrate that EC and KTP laser therapy are 
both safe and effective treatment options for SN. Although no statistically significant 
difference was observed, there was a tendency toward significance with respect 
to the clinical outcomes in favor of the KTP laser–treated SN. Patients mentioned 
significantly less pain after the laser treatment than after EC.
The fact that the vascular laser targeted the feeding vessel and the radiating vessels, 
whereas the electrocoagulation tip targeted only the feeding vessel, may explain the 
clinical results. 
The smaller amount of tissue damage caused by laser treatment and the presence 
of a water-cooled sapphire laser chill tip, causing some local anesthesia, may 
explain the difference in painfulness between the treatments. Side effects such as 
hypopigmentation, hyperpigmentation, and scar formation were not observed in our 
patients, which makes both EC and KTP suitable treatment options.
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In the last decade, pulsed lasers have become more commonly used for the treatment 
of SN.10 Tan and Vinciullo reported a retrospective study with a total clearance rate of 
93% of SN after a single PDL treatment.11 The efficacy of the KTP laser in the treatment 
of SN was first described in 24 patients, of whom 20 (83%) showed disappearance or 
moderate improvement after one treatment session.12 These results indicate that a 
PDL would be the laser of choice for SN and other telangiectasias, but in a left–right 
intrapatient treatment of PDL and KTP for facial telangiectasias, the 532-nm KTP 
laser was found to be more effective than the PDL for individual telangiectasias and 
Figure 2. Clinical photographs of spider nevi before (A) and after (B) potassium titanyl 
phosphate (KTP) treatment together with before (C) and after (D) electrocoagulation (EC) 
treatment. Photographs before (E) and after (F) KTP (19.1.1 & 19.2.1) and EC (19.1.2 & 19.2.2) 
in the same patient.
Vascular lesions
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telangiectatic erythema after each treatment.13 The KTP laser has been shown to be 
effective in the treatment of a variety of vascular lesions; the major disadvantage 
is the limited depth of skin penetration due to its short wavelength. One might 
hypothesize that if this study were performed with vascular lasers with a greater 
penetration depth, like the long-pulsed PDL or the long-pulsed Nd:YAG laser, even 
better results might have been achieved in favor of the laser, but PDL laser treatment 
may eventually result in the formation of purpura, which may result in longer 
downtime for the patient.
The benefits of various laser systems are well known, but the main point of this study is 
that treatment of SN with EC is effective, well tolerated, and more or less comparable 
with treatment with a KTP laser (figure 2). Hence, the physician who possesses only 
a hyfrecator is not undertreating his patients with SN, although treatment with KTP 
laser proved to be less painful.
In conclusion, the clinical efficacy of KTP laser and EC treatment for SN is comparable, 
although there is a tendency toward an advantage in favor of the KTP laser. KTP laser 
treatment was found to be less painful. Therefore, if a KTP laser is available, this 
might be the best choice for treatment of SN, although if a laser is not available, EC 
has proven to be a solid alternative.
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ABSTRACT
Background: Localized chronic plaque psoriasis, resistant to local therapy, may be 
very hard to treat. The treatment of these lesions with a pulsed dye laser (PDL) has 
been described before, but a comparative study between the PDL and a potent 
topical treatment has never been performed.
Objectives: To compare the efficacy of the PDL in the treatment of localized, 
recalcitrant plaque psoriasis with a potent topical therapy, using calcipotriol/
betamethasone dipropionate (Dovobet®) as an active comparator.
Methods: Eight patients with psoriasis were treated with both PDL (585 nm) and 
calcipotriol/betamethasone dipropionate in an open, intrapatient, left–right 
comparison. A plaque severity score (sum score) and photographs were used to 
document the course of therapy. Patients reported pain on a visual analogue scale. 
Results: Both treatments were well tolerated, although one patient left the study due 
to post-PDL treatment pain. A significant difference in the sum score 12 weeks after 
treatment was seen in favour of the PDL (62% vs. 19% reduction; p <0.05). Scores 
for erythema declined significantly at week 12 in both the PDL and the calcipotriol/
betamethasone dipropionate group (p <0.001). Induration and desquamation 
scores were significantly reduced at week 12 in the PDL group, without a statistically 
significant reduction in calcipotriol/betamethasonetreated lesions. The pain scores 
declined with progressive PDL treatments, although not statistically significantly.
Conclusions: PDL treatment might be considered for the treatment of localized, 
recalcitrant plaque psoriasis, when other topical therapies have failed.
Chapter 3
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Efficacy of the pulsed dye laser in the treatment of 
localized recalcitrant plaque psoriasis: a comparative 
study
INTRODuCTION
So far, no consensus exists on the position of the pulsed dye laser (PDL) in the 
treatment of psoriasis. Multiple previous studies have shown different results, ranging 
from complete remission to no improvement at all.1–7 It is difficult to compare the 
results of these studies, because they all used different treatment modalities. The 
number of treatments varied from only one treatment up to five. There was also 
a wide variation in laser parameters such as spot size (diameter 5–7 mm), energy 
fluence (2–9 J/cm2) and pulse duration (0.2–1.5 ms). There are no studies comparing 
PDL treatment with other well-known treatments for psoriasis.
In plaque psoriasis, the first comparative study was done by Zelickson et al.4 They 
compared two different pulse durations of PDL treatment with each other, using 
fluences varying between 7.5 and 8.5 J/cm2, and with triamcinolone acetonide 0.1% 
ointment twice daily for 10 weeks. Using global scores, they found a statistically 
significant clinical improvement of the PDL-treated site, compared with the 
triamcinolone-treated site. Bjerring et al. compared the PDL (0.2 ms, 2–7 J/cm2) with 
dermabrasion.6 Dermabrasion gave complete remission in five of six patients, whereas 
such improvement was reached in only three of 11 patients treated with PDL.
Neither dermabrasion nor triamcinolone acetonide 0.1% ointment, however, 
are standard treatments for psoriasis. The latter is regarded as a relatively mild 
corticosteroid for the treatment of psoriasis. There are no comparative studies 
between PDL and first-line topical treatments of psoriasis. Because PDL treatment is 
time consuming, expensive and painful, it is not a first-choice treatment for psoriasis. 
In chronic, localized, therapy-resistant plaque psoriasis, however, PDL treatment 
might provide an adequate solution.8,9 
In order to examine the position of the PDL in the treatment of localized recalcitrant 
plaque psoriasis, we compared its clinical efficacy and tolerability with an active 
comparator: calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g 
ointment (CB) (Daivobet®/Dovobet®; Leo Pharma, Ballerup, Denmark). This two-
compound product is a highly effective treatment for psoriasis. Clinical studies have 
demonstrated that up to 4 weeks of treatment with CB once daily gives superior 
efficacy and similar or better tolerability than once or twice daily application of its 
individual components.10–13
52
In a left–right comparison, patients with recalcitrant psoriasis were treated with 
both CB and the PDL. CB treatment was given for a period of 4 weeks. The number 
of PDL treatments varied between one and three, with a 2-week interval between 
treatments.
MATERIALS AND METHODS
Patients
Eight patients aged at least 18 years with stable, symmetrical, recalcitrant plaque 
psoriasis were included in the study. Recalcitrant psoriasis was defined as: “not 
responding to any topical therapy (ointments and creams), including ultrapotent 
corticosteroids and vitamin D3 derivatives and combination products or combination 
therapy with more than one topical treatment”. Patients were excluded if they 
had received systemic antipsoriatic agents within 8 weeks prior to the study, or 
phototherapy [psoralen plus ultraviolet (UV) A or UVB] within 4 weeks prior to the 
start of the study. Patients had used no topical treatment for at least 2 weeks. Other 
exclusion criteria were pregnancy, lactation and a history of photosensitivity. This 
study was approved by the medical ethics committee. Written informed consent was 
obtained from all patients.
Study design
Two weeks before the start of treatment, 10% salicylic acid in white vaseline was 
prescribed for 2 weeks in order to standardize and optimize the pretreatment 
situation for both topical treatment and laser treatment. It is particularly 
necessary to minimize scaling before PDL treatment. At the initial visit, two similar, 
contralateral psoriatic lesions of at least 12 cm2 were selected. These plaques were 
similar in terms of body localization and clinical severity score. One of the plaques 
was treated with CB once daily, for a period of 4 weeks. The contralateral lesion 
was treated with the PDL (Photogenica V laser; Cynosure, Chelmsfort, CA, U.S.A.) 
at the initial visit and after 2 and 4 weeks. A pulse duration of 0.45 ms with a 
wavelength of 585 nm was constantly used. Comparing all previous studies with 
different fluences, spot sizes and time intervals between two treatments, the best 
results were achieved with a fluence of 8.5 J/cm2, a spot size with a diameter of 5 
mm and a treatment interval of 2 weeks. In order to compare these findings with 
our own experience, a psoriatic plaque of a patient not included in our study was 
treated with four different fluences: 5.5, 6.5, 7.5 and 8.5 J/cm2. One month after 
PDL treatment, pictures were taken of the treated area and complete clearance 
was noticed at the site treated with 8.5 J/cm2 (figure 1). We therefore used an 
energy fluence of 8.5 J/cm2 and a spot size of 5 mm in all patients and during all 
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three treatments. The area treated with laser had an overlap of 10–20% per shot. 
Prior to the PDL treatment, arachis oil was applied on the psoriatic plaques, in 
order to reduce the amount of scattering. Local anaesthesia was given during and 
shortly after the laser treatment, using a cooling device (Cryo 5 cooling device; 
Zimmer Elektromedizin, Neu-Ulm, Germany).
After the 4 weeks of treatment with both PDL and CB, patients entered the follow-
up period of 8 weeks. If the PDL-treated plaque showed residual crusting at the 
planned second and third visits, PDL treatment was postponed for 1 week, until the 
crusting had resolved, for safety and to optimize efficacy. Clinical efficacy was scored 
at baseline, and after 4 and 12 weeks. Adverse events were recorded and patients 
reported pain on a visual analogue scale (VAS).
Clinical assessments
At every visit photographs of the two target plaques were taken and sum scores 
were assessed. The sum score is a cumulative measure which includes scores for 
erythema, induration (plaque thickness) and scaling on the following scale: 0, absent; 
1, minimal (very light pink, hardly any elevation, rare scale); 2, mild (light red/pink, 
slight elevation, poorly defined scale); 3, moderate (red, moderate elevation, defined 
scales); 4, severe (very red, marked ridge, heavy scaling). Finally, a global sum score 
(range 0–12) was defined as the sum of all three scores together, reflecting plaque 
severity.
Figure 1. Clinical photograph of a psoriatic plaque treated with 5.5, 6.5, 7.5 and 8.5 J/cm2 in 
four quadrants, when determining the fluence used in the present study (8.5 J/cm2).
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VAS scores (range 0–10) were used to measure the level of pain during treatment. A 
score of 0 represented a total absence of pain and 10 represented maximum pain. 
Patients reported these scores after PDL treatment.
Statistical analysis
All analyses were carried out using Statistica® statistical software, version 6.0 
(StatSoft, Tulsa, OK, U.S.A.). To compare sum scores between different moments in 
time during treatments, we performed two-way analyses of variance. If significant, 
Duncan’s post hoc comparison was performed. p < 0.05 denoted the presence of a 
statistically significant difference.
RESuLTS
Patient population
Eight Caucasian patients, four men and four women, with localized recalcitrant 
moderate-to-severe symmetrical plaque psoriasis, participated in this investigation. 
Their mean ± SEM age was 52 ± 10 years, and the mean ± SEM duration of psoriasis 
was 21 ± 8 years. One patient terminated the trial early due to an adverse event after 
the first PDL treatment. This patient considered the treatment too painful. Data of 
this patient were not analysed. A further patient required only one PDL session to 
achieve an excellent response. Two patients had PDL sessions at weeks 0, 3 and 6 
instead of 0, 2 and 4, because of residual crusting (table 1).
Sum scores during therapy
At baseline, sum scores (mean ± SEM) were 7.6 ± 0.3 in the PDL group and 7.4 ± 0.3 
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Table 1. Number of pulsed dye laser (PDL) sessions, time span between these sessions, efficacy 
and drop-out.
Patient Number of 
PDL sessions
Residual 
crusting
Postponed 
1 week
Remarks
1 3 No No Excellent response; hyperpigmentation
2 3 No No Excellent response; hyperpigmentation
3 3 No No -
4 1 No No Dropped out due to pain, data not analysed
5 3 Yes Yes PDL treatment at weeks 0, 3 and 6;
excellent response; hyperpigmentation
6 1 Yes No Excellent response; hyperpigmentation
7 3 No No -
8 3 Yes Yes PDL treatment at weeks 0, 3 and 6
Inflammatory diseases
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in the CB group. Four weeks after the start of treatment no statistically significant 
change had been observed, although a tendency to lower sum scores was seen in 
both groups. Twelve weeks after treatment, however, the sum score declined to 2.9 
± 1.4 in the PDL group (p =0.001), whereas in the CB group the sum score dropped 
only to 6.0 ± 0.7 (p =0.10). Figure 2 illustrates these results.
Differences in sum score (mean ± SEM) between the PDL and CB groups were 0.2 ± 
0.1, 0.7 ± 0.8 and 3.1 ± 1.6, at weeks 0, 4 and 12, respectively, and in favour of PDL at 
week 12. The sum score difference at week 12 was statistically significant compared 
with week 0 (p = 0.04) and week 4 (p =0.02). These results are depicted in figure 2.
Erythema, induration and desquamation
Four weeks after the start of treatment no statistically significant result was observed 
for separate erythema, induration and desquamation scores, although a tendency 
towards lower scores was observed.
Scores for erythema declined statistically significantly at week 12 in both the PDL (3.3 
± 0.2 at week 0 to 1.1 ± 0.6 at week 12; p < 0.001) and the CB groups (3.1 ± 0.1 at 
week 0 to 2.4 ± 0.2 at week 12; p < 0.01). Induration and desquamation scores were 
significantly reduced at week 12 in the PDL group, but not in the CB group (figure 
3).
Figure 2. Sum scores (0–12) during pulsed dye laser (PDL) treatment, compared with topical 
calcipotriol/betamethasone dipropionate ointment therapy (mean ± SEM). Statistical 
significance: *p = 0.001; **p = 0.04.
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Figure 3. Separate clinical scores (0–4) for the individual components: erythema (A), 
induration (B) and desquamation (C) (mean ± SEM).
Statistical significance: *p < 0.01; **p < 0.001; ***p < 0.05.
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Side-effects
Patients reported pain at the treated site as the major side-effect of PDL therapy. 
The overall pain score (mean ± SEM) on a 0–10 VAS was 6.5 ± 0.4. No correlation was 
found between pain score and treatment success. Interestingly, pain scores declined 
from 7.0 ± 0.6 after the first, to 6.7 ± 0.9 and 5.7 ± 0.8 after the second and third PDL 
sessions, respectively (p > 0.05). Four patients developed residual hyperpigmentation 
after the PDL treatment.
Long-term follow-up
After more than 6 months of follow-up, the four patients with a complete response 
to PDL still had clearance of the treated plaque. Hyperpigmentation was still visible. 
However, three of these four patients had needed systemic treatment for an 
exacerbation of their psoriasis, and therefore the follow-up observation on the PDL-
treated plaque was no longer reliable.
DISCuSSION
In the present study patients were treated for 4 weeks with the PDL and CB in an 
open, intrapatient, left–right comparison. After 4 weeks of treatment, no statistically 
significant result was observed in either treatment. The majority of patients (five 
out of seven) received their third and last PDL treatment only at week 4; it is thus 
likely that at week 4 the clinical results of the PDL treatment were not yet apparent. 
The results after 4 weeks of CB treatment, however, were unexpected. Although a 
tendency to a decline in sum score was observed, there was no statistically significant 
improvement of the psoriatic lesions. This is in contrast with earlier studies, in which 
CB showed good results after 4 weeks of treatment.10–13 The explanation for this may 
be that we selected patients with plaque psoriasis that had previously been resistant 
to potent topical treatments. Secondly, it is possible that patients’ compliance may 
not have been optimal. Although all patients claimed to have applied the ointment 
once daily, we did not check the residual ointment after the 4 weeks of topical 
treatment.
In contrast, after 8 weeks of follow-up, at week 12, the sum score had significantly 
declined further in the PDL group. We also observed a reduction in the CB-treated 
group, but this decline was not significant. Remarkably, in both groups the score for 
erythema declined significantly after 12 weeks, whereas induration and desquamation 
scores declined significantly only in the PDL group.
Four of seven patients reached complete clearance of the psoriatic lesions 8 
weeks after the final laser treatment. In these patients, all of whom had skin type 
I, II or III, there was some degree of hyperpigmentation visible at the treated 
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area. Mild hyperpigmentation was also present in the patients treated with PDL 
in previous studies.2–4 Although some studies mentioned other side-effects such 
as hypopigmentation and atrophic scarring, we did not see these effects in our 
patients.3,4 Patients who had complete remission of the PDL-treated plaque had a 
prolonged remission: after approximately 6 months of extra follow-up there were 
still no signs of relapse.
There was a tendency towards a decline in the reported pain scores after successive 
laser treatments, although this was not significant. Pain has also been mentioned 
in previous studies as a disadvantage of the PDL treatment. By providing local 
anaesthesia with a cooling device during and shortly after the laser procedure, our 
patients considered the laser treatment to be reasonably tolerable.
Studies on the efficacy of treating chronic psoriatic plaques with the PDL, compared 
with a first-line topical therapy for psoriasis, have not previously been performed. 
Although we noticed a significant improvement in the laser-treated areas at week 
12, compared with those treated with the active comparator, the utility of the PDL 
as a standard therapy for psoriasis is limited. Due to the small spot size and the 
post-treatment pain, laser treatment has to be restricted to only circumscribed and 
therapy-resistant psoriatic plaques.
Limitations of the present study include the lack of blinding, the small patient group 
and the possible poor compliance to topical treatment. Moreover, sum scores might 
have been influenced by the pretreatment with 10% salicylic acid, which is necessary 
for PDL treatment on severely scaling plaques. However, pretreatment might also 
have enhanced the penetration of CB. 
In conclusion, PDL treatment might be considered for the treatment of localized, 
recalcitrant plaque psoriasis, when topical therapies have failed or are contraindicated. 
The treatment is well tolerated although pain and hyperpigmentation can be 
experienced. These side-effects were acceptable in most patients.
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ABSTRACT
Background: Selective photothermolysis of diseased capillaries by pulsed dye laser 
(PDL) treatment has been described as a mechanism for long-lasting clearance of 
psoriatic plaques.
Aim: To evaluate PDL and a two-compound formulation of calcipotriol/betamethasone 
dipropionate ointment for the treatment of localized, recalcitrant plaque psoriasis. 
Methods: Eight psoriatic patients were treated for 4 weeks with both PDL and 
topical calcipotriol/betamethasone dipropionate in an open, intra-patient, left-right 
comparison. Biopsies were analyzed for T-cell subsets, cells expressing NK-receptors, 
epidermal proliferation, differentiation and epidermal thickness. 
Results: After active treatment, both treatments showed statistically significant, but 
comparable improvements of T-cell subsets, epidermal proliferation, differentiation 
and epidermal thickness. In line with the clinical results, after an 8-week follow-up 
period statistically significant further reductions were observed for dermal CD3+, 
CD4+, CD45RO+, CD2+ T cells, epidermal CD3+, CD8+, CD45RO+, CD2+, CD25+ T 
cells and the epidermal parameters for the PDL-treated plaques, in contrast to the 
topically treated plaques. 
Conclusion: After 8 weeks of follow-up, PDL treatment for localized and recalcitrant 
plaque psoriasis resulted in persistent reductions of activated and memory effector 
T-helper cells in the dermis, cytotoxic T cells in the epidermis, and normalization of 
epidermal proliferation and keratinization, in contrast to treatment with calcipotriol/
betamethasone dipropionate ointment. 
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Pulsed dye laser versus treatment with calcipotriol/
betamethasone dipropionate for localized refractory 
plaque psoriasis: effects on T-cell infiltration, 
epidermal proliferation and keratinization 
INTRODuCTION 
Pulsed dye laser (PDL) treatment for vascular disorders of the skin has been an 
accepted treatment modality since the early 1980s.1 The PDL-specific 585 nm 
wavelength of laser light is preferentially absorbed by the oxyhemoglobin present 
in small vessels in the dermis, where the heat leads to coagulation of and ablation 
of blood vessels (selective photothermolysis).1,2 A histological hallmark of psoriasis is 
dilatation and tortuosity of the capillary bed in the dermis, which has been reported 
to be an early phenomenon in the pathogenesis of psoriatic plaques.3-5 When these 
diseased capillaries are eliminated by PDL treatment, the severity of psoriatic plaques 
is likely to improve.6,7 
Immunohistochemical assessments of the effect of PDL treatment on severe 
recalcitrant psoriasis have sparsely been reported.8,9 Clinical efficacy of PDL 
treatment for psoriasis is still controversial. Some reports indicate no improvements 
at all, whereas others report long-lasting clearance of plaques.8-14 Only three clinical 
comparative studies have been performed so far. PDL treatment showed higher 
clinical efficacy compared with topical triamcinolone acetonide 0.1% treatment 
in a study by Zelickson et al., whilst dermabrasion had better clinical results than 
treatment with PDL in a study by Bjerring et al.9,14 Erceg et al. gave a detailed report 
of the clinical results of the present study. In that report, PDL showed an outstanding 
efficacy as compared to calcipotriol/betamethasone dipropionate ointment. It was 
concluded that PDL treatment might be considered for the treatment of localized, 
therapy-resistant plaque psoriasis, when other topical therapies have failed.15 
Two studies have examined psoriatic skin biopsies during and after PDL treatment. 
First, Zelickson et al. observed clinical and histological improvement using hematoxylin 
and eosin (HE) stainings and confocal laser microscopy. Various histopathological 
features improved, including the diseased dermal vasculature.9 Furthermore, Hern 
et al. assessed markers for angiogenesis, lymphocyte infiltration (CD4 and CD8), 
epidermal thickness and keratinocyte proliferation, before and 2 weeks after three 
PDL exposures to treat psoriasis. Vascular improvements were found to be limited 
to the papillary dermis, whereas no changes in the upper reticular dermis were 
observed. Adhesion molecules did not change during treatment. The CD4+ and CD8+ 
T-cell infiltrate exclusively reduced in the superficial dermis, but not in the epidermis 
62
Chapter 3
or in the reticular dermis. Epidermal thickness improved, whereas keratinocyte 
proliferation was not significantly altered after treatment. Hern et al. hypothesized 
that dermal capillary changes alone are not likely to be causal in psoriasis, but might 
be important in the facilitation of traffic of pathogenic T cells into the skin and in 
perpetuation of the psoriatic process.8 Vissers et al. showed an immunohistochemical 
analysis of the effect of treatment with calcipotriol, once daily, and betamethasone, 
once daily, on psoriatic plaques.18 Yet, there are no studies available that examined 
the dynamics of T-cell subsets during treatment with the two-compound formulation, 
which contains both calcipotriol and betamethasone dipropionate.
To study the dynamics of activated (CD2, CD25) and memory effector (CD45RO) 
T cells of the T-helper (CD4) and cytotoxic (CD8) subset and epidermal markers for 
proliferation (Ki67) and differentiation (K10) during PDL treatment, we performed an 
intra-patient left/right comparison: one plaque treated with PDL and the contralateral 
plaque with a well-established two-compound topical treatment, calcipotriol 50 µg/g 
and betamethasone dipropionate 0.5 mg/g ointment, once daily.17,18 
METHODS
Patients 
Eight patients of at least 18 years old with stable, symmetrical, recalcitrant plaque 
psoriasis were included in the present study. Recalcitrant psoriasis was defined 
as “not responding to any topical therapy (ointments and creams), including ultra 
potent corticosteroids and vitamin D3 derivatives and combination products or 
combination therapy with more than one topical treatment”. Patients were not 
treated with systemic anti-psoriatic medication (stopped ≥ 8 weeks prior to the study), 
phototherapy (discontinued ≥ 4 weeks prior to the study start), or topical treatment 
(stopped at least 2 weeks prior to the baseline visit). Other exclusion criteria were 
pregnancy, lactation and a history of photosensitivity. The medical ethics committee 
approved the present study and written informed consent was obtained from all 
patients. 
Study design 
Two weeks before the start of treatment, 10% salicylic acid in white vaseline was 
prescribed for two weeks in order to standardize and optimize the pretreatment 
situation for both topical treatment and laser treatment. For PDL treatment especially 
it is essential to minimize scaling. At the initial visit, two similar, contralateral psoriatic 
lesions of at least 12 cm2 were selected. These plaques were controlled, in terms of 
body localization and clinical severity score. One of the plaques was treated with 
calcipotriol/betamethasone dipropionate ointment (Daivobet®/Dovobet®; LEO 
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Pharma, Ballerup, Denmark), once daily, for a period of 4 weeks. The contralateral 
lesion was treated with the PDL (Photogenica V laser; Cynosure, Chelmsfort, CA, 
USA) at the initial visit, and after 2 and 4 weeks. An energy fluence of 8.5 J/cm2, a 
pulse duration of 0.45 ms with a wavelength of 585 nm, a spot size of 5 mm with 
an overlap of 10-20 % per shot was constantly used in all patients and during all 
treatments. Local anesthesia was given during and shortly after the laser treatment, 
using a cooling device (Cryo 5 cooling device; Zimmer Elektromedizin).
After the 4 weeks of treatment with both PDL and calcipotriol/betamethasone 
dipropionate ointment patients entered the follow-up period of 8 weeks. If the PDL-
treated plaque showed residual crusting at the planned second and third visit, PDL-
treatment was postponed for one week, until the crusting had resolved, in order to 
secure safety and to optimize efficacy. Clinical efficacy was assessed and biopsies 
were taken at baseline, and after 2, 4 and 12 weeks.
Clinical assessment 
At baseline and at weeks 2, 4 and 12, clinical severity assessments of the treated 
plaques were performed. SUM-scores (0-12) were obtained by one single observer 
during the whole study period. SUM-scores represent the cumulative score for 
erythema (0-4), induration (0-4) and desquamation (0-4). A SUM-score of 0 represents 
“no psoriasis” and a SUM-score of 12 reflects the ‘worst imaginable clinical severity 
of the psoriatic plaque’. 
Biopsies 
All biopsies (4 mm) were taken at a central, representative site in the target lesions. At 
Antibody Concentration Specificity Marker for Source
MIB-1 1:200 Ki67 Keratinocyte proliferation DAKO, Copenhagen, Denmark
RKSE60 1:100 Keratin 10 Normal keratinization Monosan Laboratories, Uden, 
The Netherlands
UCHT1 1:100 CD3 Pan T cells DAKO, Copenhagen, Denmark
MT310 1:200 CD4 Helper T cells DAKO, Copenhagen, Denmark
DK25 1:200 CD8 Cytotoxic T cells DAKO, Copenhagen, Denmark
UCHL1 1:100 CD45RO Memory effector T cells DAKO, Copenhagen, Denmark
4KB5 1:200 CD45RA Naive T cells DAKO, Copenhagen, Denmark
MT910 1:200 CD2 Pan T cells, but upregulated on activated 
T cells
DAKO, Copenhagen, Denmark
ACT-1 1:200 CD25 Il-2 receptor, early activation marker DAKO, Copenhagen, Denmark
HP-3D9 1:100 CD94 NK cells and some T cells DAKO, Copenhagen, Denmark
191B8 1:100 CD161 NK-T cells Immunotech, Marseille, France
110416 1:100 GITR/
TNFRSF18
Glucocorticoid-induced tumor necrosis 
factor receptor, inhibitory receptor of 
regulatory T cells, some macrophages
R&D Systems, Minneapolis, 
USA
Table 1. Used monoclonal antibodies for immunohistochemistry.
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baseline, two biopsies were taken: one of distant uninvolved skin and one of lesional 
psoriatic skin. At weeks 2, 4 and 12, two biopsies were taken, only of both treated 
plaques. The distant uninvolved skin served as a control to compare the after-treatment 
situation with the baseline values. Before the biopsy procedure, local anaesthesia was 
given (xylocaine/adrenaline 1:100.000). Skin defects were closed with one suture. The 
samples were embedded in Tissue Tek OCT compound (Miles Scientific, Naperville, IL, 
USA), instantly frozen in liquid nitrogen and stored at -80 °C until use.
Immunohistochemical staining 
Sections were sliced 7 µm thick and were air-dried for 30 minutes. Then the sections 
were fixed in cold acetone for 10 minutes. After blocking 5 minutes for endogenous 
peroxidase, using 0.2% sodium azide, they were washed in PBS for 10 minutes. 
Subsequently, sections were incubated with the primary antibodies for 1 hour. The 
monoclonal antibodies used are listed in table 1. Sections were washed in PBS for 
15 minutes. The secondary IgG labeled polymer HRP anti-mouse EnVision+ (DAKO, 
Copenhagen, Denmark) was added for 30 minutes. The sections were washed 
again for 15 minutes in PBS. To visualize the staining we used AEC+ high sensitivity 
substrate chromogen for 10 minutes (DAKO). Counterstaining was performed with 
Mayer’s hematoxylin (Sigma, St Louis, MO, USA). The sections were washed in tap 
water, dried and mounted in glycerol gelatin (Sigma).
HE staining 
Furthermore, from each patient we performed hematoxylin and eosin (HE) stainings. 
After dehydration in alcohol and histosafe, these sections were mounted in 
Permount. With these HE sections, it was verified that the baseline biopsies fulfilled 
the psoriasis-specific histological criteria. 
Manual quantification 
Quantification of T-cell subsets was performed with light microscopy at 200X 
magnification. In all sections CD3, CD4, CD8, CD45RO, CD45RA, CD2, CD25, GITR, 
CD94 and CD161 positive cells in the epidermis were counted from the basement 
membrane up to the stratum corneum across the whole section (4 mm). Cells in 
the dermis were counted from the basement membrane down to 100 µm under 
the basement membrane and also across the whole section. Quantitative cell counts 
were expressed in “positive cells per mm skin length”.
Digital image analysis 
In order to analyze Ki67 positive cells, three representative digital photographs 
were made at 100x magnification. Each photograph was analyzed using IP-lab 
software. A line, with known length and following the stratum basale, was drawn 
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after choosing a representative “region of interest” (ROI). All positive cells above 
this line were counted and expressed in the unit “positive cells per mm length of 
basement membrane”. For quantification of keratin 10 (K10) positive cells, digital 
photographs were made at 50x magnification. Using IP-lab software a ROI was set 
for the analysis of K10, in a representative area of the particular section. The ROI was 
chosen in only the epidermal compartment and possible dermal tissue in the ROI was 
subtracted. The total area of the epidermal compartment in the ROI and the K10+ 
area were measured using IP-lab software. Epidermal differentiation was defined as: 
the percentage K10+ epidermal surface area. Epidermal thickness was measured in 
HE sections with the help of IP-lab software, by calculating the means of the three 
smallest and three largest vertical lengths of the epidermis, without the stratum 
corneum. The mean value per section was determined “epidermal thickness”. 
Statistical analysis 
All analyses were carried out using Statistica® statistical software, version 6.0. Two-
Figure 1. Dermal counts for T-cell subpopulations and cells expressing NK-receptors during 
treatment with PDL and calcipotriol/betamethasone dipropionate ointment, at baseline, after 
2 and 4 weeks of treatment, and after an 8-week follow-up period.
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way analyses of variance (ANOVA) were performed. If significant, Duncan’s post-hoc 
comparison was performed. A p-value of less than 0.05 denoted the presence of a 
statistical significant difference. 
RESuLTS
Patient population
A total of eight patients with recalcitrant and symmetrical plaque psoriasis 
participated; four were male and four were female. One patient early dropped out 
due to an adverse event (pain) at the PDL-treated plaque. The histology (HE) of 
Figure 2. Epidermal counts for T-cell subpopulations and cells expressing NK-receptors during 
treatment with PDL and calcipotriol/betamethasone dipropionate ointment, at baseline, after 
2 and 4 weeks of treatment, and after an 8-week follow-up period.
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all baseline biopsies of the seven evaluable patients fulfilled the psoriasis-specific 
criteria. Two patients had PDL sessions at week 0, 3 and 6 instead of 0, 2 and 4, 
because of residual crusting. 
Clinical assessment 
After 12 weeks, the mean SUM-score reduced 62% in the PDL-treated plaques 
(p=0.001), whereas the reduction of the SUM-score was 19% (p =0.10) in the plaques 
treated with calcipotriol/betamethasone dipropionate. A more detailed description 
of the clinical results has been reported elsewhere.15
 
T-cell subsets 
Dermis. In the dermal compartment, statistically significant reductions of T-cell 
subpopulations were observed for both treatments after the active treatment period 
(week 4). At week 4, there were no statistical significant differences between the 
treatments. After 8 weeks of follow-up, statistically significant higher reductions of 
CD3+ (70% vs. 34%; p <0.01), CD4+ (68% vs. 27%; p <0.05), CD45RO+ (69% vs. 24%; 
p <0.05) and CD2+ (66% vs. 22%; p <0.05) T cells were observed for PDL compared 
with calcipotriol/betamethasone dipropionate therapy. In other words: the anti-T-
cell effect in de PDL-treated plaques further reduced, whereas T-cell accumulation in 
the calcipotriol/betamethasone dipropionate treated plaques stabilized after follow-
up (figure 1).
Epidermis. Additionally, epidermal T-cell subsets significantly declined towards week 4 
during both treatments. The reductions by both treatments did not show statistically 
significant differences. However, after the 8-week follow-up period the PDL-treated 
plaques showed significantly higher reductions of CD3+ (84% vs. 42%; p <0.01), CD8+ 
(88% vs. 46%; p <0.01), CD45RO+ (89% vs. 35%; p <0.05), CD2+ (86% vs. 59%; p <0.05) 
and CD25+ (89% vs. 26%; p <0.01) T-cell subpopulations in comparison to the plaques 
treated with topical calcipotriol/betamethasone dipropionate ointment (figure 2).
NK-T cells 
Dermis. During and after treatment, both CD94+ and CD161+ cells in the dermis 
showed a tendency of reduction compared to baseline. At week 12, no statistical 
significant difference was observed between the treatments (figure 1).
Epidermis. Low numbers of CD94+ and CD161+ cells were quantified in the epidermis 
and did not significantly reduce during either treatment modality, neither at week 4, 
nor at week 12. There were no differences between the treatments (figure 2).
Epidermal parameters 
Epidermal proliferation. The mean number of Ki67+ nuclei was significantly reduced 
at week 4 during each treatment, but the difference between both treatments was 
68
not statistically significant. At week 12, in contrast, PDL-treated plaques showed a 
statistically significant lower mean number of Ki67+ nuclei than the plaques treated 
with topical calcipotriol/betamethasone dipropionate (53% vs. 2% reduction from 
baseline; p <0.001) (figure 3A).
Epidermal differentiation. The mean percentage of K10+ epidermal area was 
significantly increased at week 4 during both treatments. After 8 weeks of follow-
up, a superior improvement was observed for the PDL-treated plaques compared 
with calcipotriol/betamethasone dipropionate ointment (24% vs. -3% improvement 
in K10+ epidermal area from baseline; p <0.001) (figure 3B).
Epidermal thickness. The thickness of the epidermis showed a 59% reduction for 
PDL-treated plaques and a 31% reduction for the plaques treated with calcipotriol/
bethametasone dipropionate, respectively, at week 12 (p <0.001) (figure 3C).
DISCuSSION 
In the present study, generally improvements were observed for PDL treatment for 
activated memory effector T cells, already after 2 and 4 weeks of treatment. A similar 
response was noticed for the topical treatment with calcipotriol/betamethasone 
dipropionate. However, after an 8-week follow-up period, dermal CD3+, CD4+, CD45RO+, 
CD2+ T cells, epidermal CD3+, CD8+, CD45RO+, CD2+, CD25+ T cells, epidermal 
proliferation (Ki67), and epidermal thickness further reduced and keratinization (K10) 
improved, in the PDL-treated plaques, but not in the calcipotriol/betamethasone 
dipropionate treated plaques. These differences were statistically significant. 
A tortuous capillary bed, elongation of the rete ridges, hyper- and parakeratosis 
of the epidermis and the influx of immunocytes in the dermis and epidermis are 
histological hallmarks of psoriasis.19,20 Recent insights have mainly pointed towards 
a potential initiating role for T cells in the pathogenesis of psoriasis.21,22 However, 
there is some evidence that microvascular changes occur well before overt T-cell 
Figure 3. (A) Epidermal proliferation (number of Ki67+ epidermal cells); (B) epidermal 
differentiation (percentage of K10+ epidermis); and (C) epidermal thickness (mm) during 
treatment with PDL and calcipotriol/betamethasone dipropionate ointment, at baseline, after 
2 and 4 weeks of treatment, and after an 8-week follow-up period.
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infiltration and epidermal hyperplasia in the process of formation of a psoriatic 
plaque.3-5 Therefore, it may be hypothesized that destroying the diseased capillaries 
helps preventing T cells to extravasate into the skin. In turn, this might be a reason for 
the long-standing therapeutic effect of PDL in psoriasis and the observed prolonged 
immunohistochemical and clinical improvements. 
The results of the present study are greatly in line with our previous report on 
clinical efficacy of the PDL versus treatment with calcipotriol/betamethasone 
dipropionate ointment.15 All immunohistochemical effects preceded the clinical 
effects. With respect to the dynamics of T-cell subpopulations during PDL and 
treatment with calcipotriol/betamethasone dipropionate the present results are in 
line with studies reported by Hern et al. (PDL) and Vissers et al. (calcipotriol and 
betamethasone dipropionate), although there are some discrepant outcomes as 
well.8,16 In the present comparative study, the most intriguing finding in the PDL-
treated plaques is the highly reduced number of T-helper cells (CD4+) in the dermis 
and cytotoxic T cells (CD8+) in the epidermis, memory effector T cells (CD45RO+) 
and T cells with markers of activation (CD2, CD25). Previously, Hern et al. reported a 
reduction of CD4+ and CD8+ T cells restricted to the psoriatic dermis.8 However, the 
study design included only 2 weeks of follow-up, which might have been too short. 
Cells expressing NK-receptors CD94 and CD161 did not show different responses to 
PDL and calcipotriol/betamethasone dipropionate ointment therapy in the present 
study. Also GITR-expressing cells (up-regulated and inhibitory on regulatory T cells) 
were very few in number and did not show differential responses to both treatments. 
Conversely, Vissers et al. observed a reduction of CD94+ and CD161+ NK-T cells in 
the dermis after combined treatment with calcipotriol ointment, once daily, and 
betamethasone dipropionate ointment, once daily.16 There are no comparable 
studies for the two-compound formulation of the ointment used in our study. 
In the present study, the degree of response to therapy was at variance. It appeared 
that four of the seven evaluated patients, those patients with complete clearance 
at week 12, could be determined as ‘responders’. Responder patients showed 
far more normalization of epidermal thickness, proliferation and differentiation, 
together with a significantly more reduced T-cell infiltrate, than those patients that 
did not completely respond to PDL. Interestingly, it was observed that a reduction of 
epidermal T-cell subsets correlated best to overall reduction of plaque severity. This is 
in line with earlier studies.23-25 Apparently, normalization of keratinocyte behavior and 
the observed reduction of epidermal T cells are indirect results, secondarily caused 
by an inhibited extravasation of dermal T cells due to selective photothermolysis of 
the diseased psoriatic capillaries by PDL treatment. Indeed, after long term follow-up 
the clinical and immunohistochemical effect of PDL was still persistent and ongoing. 
A negative feature was the drop-out of one patient due to pain experienced during 
and after PDL treatment.
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Unfortunately, we have no immunohistochemical data on even longer follow-
up duration. Nevertheless, clinical observations even after 1 year of follow-up of 
responder patients still showed marked improvements of the treated plaque.15 
Indeed, recent studies on PDL for psoriasis indicate response rates between 57% and 
82%, and remission may extend up to 15 months.26 We have to disclose some minor 
shortcomings: the selection of ‘recalcitrant’ psoriatic patients; pre-treatment with 
10% salicylic acid in white vaseline, which has recently been proven beneficial for 
the treatment of psoriasis with PDL;27 an expected higher compliance of PDL versus 
calcipotriol/betamethasone dipropionate treatment; and the low number of treated 
patients. 
In summary, an evaluation 8 weeks after a 4-week treatment course with PDL for 
localized and recalcitrant plaque psoriasis resulted in persisting reductions of activated 
T-helper cells in the dermis and cytotoxic T cells in the epidermis, together with 
normalization of epidermal proliferation, differentiation and epidermal thickness, 
well beyond the improvement achieved with topical calcipotriol/betamethasone 
dipropionate ointment.
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ABSTRACT
Objective: The purpose of this study was to achieve a validated clinical and image 
scoring system for a single chronic discoid lupus erythematosus (CDLE) lesion. 
Methods: Fifteen patients with a CDLE lesion were scored twice by four observers 
and clinical photographs were taken. These pictures were assessed by the same 
four observers at two time points. Patients were scored using the DLE-Skin Score 
(DLE-SS). In addition, the DLE-Photo Score (DLE-PS) was calculated. Statistical 
analysis was carried out by measuring inter- and intra-observer agreement for both 
methods and by measuring the correlation between the DLE-SS and DLE-PS.
Results: Both the DLE-SS and DLE-PS proved reliable methods in the assessment 
of CDLE. The inter-observer variability of the DLE-SS and DLE-SS was low. The 
intra-observer. Variability was estimated to be 0 in both methods. The correlation 
coefficient between the DLE-SS and DLE-PS was high (0.81). 
Conclusion: Both the DLE-SS and the DLE-PS are reliable and easy-to-use methods to 
score disease activity in CDLE patients, and can be used in monitoring single target 
lesions in clinical trials.
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Validation of clinical and image skin scoring systems 
for a single chronic discoid lupus erythematosus 
lesion
INTRODuCTION
Chronic discoid lupus erythematosus (CDLE) is a skin disorder, which consists of well-
defined erythematous, scaly plaques that tend to heal with scarring, atrophy and 
pigmentary changes. These changes can be very disfiguring; therefore, evaluation of 
therapy and development of more effective new treatments are important. CDLE is 
the most common form of cutaneous lupus and is in most cases restricted to the skin 
only. Approximately 5% of the patients first diagnosed with CDLE later show systemic 
involvement and are diagnosed as having systemic lupus erythematodes (SLE).1,2 To 
monitor the effects of therapy in patients with CDLE, determination of the skin lesion 
status is necessary.
In most trials or reports in which the effect of new topical or surgical treatments 
for CDLE is measured, the investigators usually treat one single target lesion.3-7 To 
evaluate these new treatment modalities a detailed description of this single lesion is 
required. Therefore, a simple validated scoring system that focuses on a single lesion 
is important. The well-developed Cutaneous Lupus Erythematosus Disease Area and 
Severity Index (CLASI) measurement instrument8 is very extensive and not focused 
on one single lesion.
In this study, a new scoring system for CDLE has been designed in which all prominent 
features, namely erythema (E), induration (I), scaling (S) and atrophy (A), are represented 
and scored separately, in a detailed way; the sum of these is called the DLE-Skin Score 
(DLE-SS). Because of the fact that induration cannot be measured from a picture and 
photograph images are often used in clinical trials, we designed a modified scoring 
system for the photographed lesions: the DLE-Photo Score (DLE-PS).
Both scoring methods (DLE-SS and DLE-PS) were validated for their concordance 
between observers and within observers and the degree of agreement between skin 
score and photo score was calculated.
PATIENTS AND METHODS
Patients
All patients with a histologically confirmed CDLE who had visited the Department 
of Dermatology at the St Radboud University Hospital over the past 2 years were 
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Erythema (E) 0 = none
1 = mild (light red)
2 = moderate (red)
3 = severe (very red)
4 = very severe (extremely deep red)
Induration (I) 0 = none
1 = slight (slightly increased compared with normal surrounded skin)
2 = moderate (easily palpable elevation)
3 = marked (definitely elevated lesions with hard, sharp edges to plaques)
4 = very marked (elevation with very hard, sharp edges to plaque)
Scaling (S) 0 = none
1 =mild
2 = moderate
3 = severe
4 = very severe
Atrophy (A) 0 = none
1 = mild: barely noticeable
2 = moderate: coarser, noticeable
3 = severe: thick, shiny, visually obviously
4 = very severe: high level of disfigurement
contacted by means of a letter. The voluntarily responding patients (33%) were 
included in the study. To be eligible for the study, patients had to have at least one 
CDLE lesion.
A total of 15 patients (six men and nine women) participated in this study. The 
duration of the CDLE ranged from 14 months to 22 years. The number of lesions 
varied from one single lesion to nine lesions. In case of multiple lesions, the most 
prominent lesion was selected.
All patients were scored twice in a randomly distributed order at a 1-hour interval by 
four independent observers: two consultant dermatologists, one chief resident and 
one junior resident in dermatology. During this visit clinical photographs were taken. 
These pictures were assessed by the same four independent observers a month after 
the initial visit and 1 week later for the second time.
Clinical score
The DLE-SS is a cumulative measure which includes scores for erythema (E), induration 
or plaque thickness (I), scaling (S) and atrophy (A) on a 5-point-scale ranging from 0 
to 4 (see table 1).
The DLE-SS is calculated as Σ(E + I + S + A). This scoring system is partially based on 
the scoring method which Heffernan et al. used in their study3 and extended with a 
scaling score. The possible minimum score is 0, representing no affected skin, and 
the maximum score is 16.
Table 1. DLE-SS = Σ(E + I + S + A). DLE-PS = Σ(E + S + A).
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Photograph score
Photographs were taken of the scored lesions, using a Nikon D1 105 digital camera 
under standardized conditions. After one month the photographed lesions were 
scored by the four observers and 1 week later using the same computer.
DLE-PS is the sum of erythema (E), scaling (S) and atrophy (A) using the same five-
point scale for these parameters as described in table 1. The DLE-PS is calculated as 
Σ(E + S + A).
Statistical analysis
The DLE-SS and DLE-PS were analysed statistically as follows.
Observer agreement for both methods was analyzed by considering the total amount 
of variation present in the ratings and estimating the amount of variability from the 
patients (σ2p), the amount of the repeating of measurements (σ
2
r), the amount of 
the observers (σ2o), and the amount of random error (σ
2
e). In a reliable method, the 
inter-observer variability (variation of clinicians) and the intra-observer variability 
(variation from repeated measurements) should be low, whereas the variability 
caused by diversity of patients should be high.
All variances mentioned were estimated with the maximum likelihood variance 
components estimation procedure of the SAS-package (SAS Institute Inc., Cary, NC, 
USA). Results for the various sources of variation are presented as the percentage of 
the total variance (σ2p+ σ
2
o + σ
2
r + σ
2
e).
For analysis of correlations between the DLE-SS and DLE-PS, the Spearman correlation 
coefficient was used.
RESuLTS
Fifteen patients (six men and nine women) participated in this study. Their mean age 
was 50.5 (± 2.37 SEM) years, the youngest was 36 years old and the oldest was 69 
years old. The duration of the CDLE lesions ranged from 14 months to 22 years, with 
a mean of 10.46 (± 2.08 SEM) years. The number of active lesions ranged from one to 
nine, with a mean of 4.3 (± 1.10 SEM). Most of the scored lesions were located on the 
face (10), whereas four lesions were on the vertex and one on the back.
Table 2. Percentage of total variance from observers, repetition, patients and random error.
Variance (% of total) DLE-SS DLE-PS
Variance from patients 80 86
Variance from observers 6 2
Variance from repetition 0 0
Variance from random error 14 12
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The percentage of variance from the patients was high: 80% (DLE-SS) and 86% (DLE-
PS). This means that the amount of variation from observers, repeated measurements, 
and random error was low. The inter-observer variability, expressed as the percentage 
of variance from observers, was 6 (table 2).The intra-observer variability, which is the 
variation from repetition of measurements by the same observer, was estimated to 
be 0 (table 2).The inter-observer variability in the scores from the pictures was only 
2, and intra-observer variability was estimated as 0.
The correlation coefficient between the DLE-SS and DLE-PS is approximately 0.81. If 
only erythema, scaling and atrophy of the DLE-SS (modified DLE-SS) were correlated 
to the DLE-PS, a correlation of 0.86 was found.
The correlations between the DLE-SS (with and without the induration component) 
and DLE-PS for the different observers are summarized in table 3.
DISCuSSION
To assess disease activity and efficacy of therapy in one single CDLE lesion it is 
important to use standardized outcome measures that are reliable, clinically 
meaningful and feasible to use.
Both the DLE-SS and DLE-PS proved reliable methods in the assessment of a single 
CDLE. The inter-observer variability of the DLE-PS was low, even lower than the inter-
observer variability of DLE-SS (2.0 vs 6.0). This slight difference can be explained by 
the fact that the DLE-PS had one variable less, namely induration. The intra-observer 
variability was very low in both scores. This low intra and inter-observer variability 
means that this method can reliably be used by the same observer at different 
moments and by different investigators as well.
Correlation between DLE-SS and DLE-PS was 0.81. If only the erythema, scaling 
and atrophy of the DLE-SS (modified DLE-SS) were correlated with the DLE-PS, a 
correlation of 0.86 was found. It is striking that the absence of the variable induration 
in the DLE-SS (modified DLE-SS) does not result in a higher correlation coefficient 
Chapter 3
Table 3. Spearman correlation coefficients between DLE-SS and DLE-PS (95% confidence 
interval). Modified DLE-SS = DLE-SS without induration.
DLE-SS vs DLE-PS Modified DLE-SS vs DLE-PS
Observer 1 0.81 (0.51-0.93) 0.84 (0.58-0.95)
Observer 2 0.83 (0.55-0.94) 0.90 (0.72-0.97)
Observer 3 0.80 (0.49-0.93) 0.85 (0.60-0.95)
Observer 4 0.79 (0.47-0.93) 0.83 (0.55-0.94)
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between DLE-SS and DLE-PS. In the ideal situation, one would expect a correlation of 
1. The fact that the correlation coefficient between the two methods is not 1, implies 
that both methods cannot easily be exchanged and are not identical.
Besides, the high correlation (0.86) between the modified DLE-SS and DLE-PS is partly 
due to the fact that our patients were photographed under ideal conditions by the 
same professional photographer. We realise that these conditions are not always 
accessible in all clinics.
The DLE-SS has a great advantage compared with the DLE-PS as it is obvious that in 
the DLE-PS the induration cannot be measured. The difference in induration before 
and after a treatment is an important outcome measure, which is neglected if only 
photographs are scored. 
In conclusion, both the DLE-SS and the DLE-PS are reliable and easy-to-use methods 
to score disease activity in CDLE patients. We prefer, however, the DLE-SS, because 
this method also measures induration, which is a key feature in disease activity. In 
trials and reports in which one initial target lesion is used as an outcome measure, 
the DLE-SS and the DLE-PS are very suitable validated methods.
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ABSTRACT
Background: Treatment of chronic discoid lupus erythematosus (CDLE) with a pulsed 
dye laser (PDL) has shown promising results, although outcomes in previous studies 
were not validated and laser parameters were inconsistent.
Objective: We conducted an open prospective study to assess the efficacy and safety 
of PDL for the treatment of recalcitrant CDLE, using a validated scoring method and 
a fixed treatment schedule.
Methods: Twelve patients with active CDLE lesions were treated with PDL (585 nm, 
fluence 5.5 J/cm2, spot size 7 mm) 3 times with an interval of 6 weeks followed by 
a 6-week follow-up period. Treatment outcomes were evaluated by 3 observers 
using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index 
(CLASI). Cosmetic results and adverse events were recorded.
Results: A significant decline in ‘‘active’’ CLASI was observed after 6 weeks, after 
12 weeks, and at follow-up. Baseline active CLASI was 4.4 6 0.2 (mean ± SEM), 
reaching 1.3 ± 0.3 after follow-up (p <.0001). Individual scores for erythema and 
scaling/hypertrophy significantly declined 6 weeks after treatment. The ‘‘damage’’ 
CLASI (dyspigmentation, scarring, and atrophy) did not show any significant change 
during or after therapy. The observed clinical improvement was confirmed by two 
independent observers by clinical assessment of photographs (r = 0.87 and r = 0.89; 
both p <.05). The treatment was well tolerated, only minimal pain was reported, and 
the cosmetic result was fair.
Limitations: Small sample size and short follow-up duration were limitations.
Conclusion: PDL treatment is an effective and safe therapy for patients with refractory 
CDLE.
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Efficacy and safety of pulsed dye laser treatment for 
cutaneous discoid lupus erythematosus
INTRODuCTION
Chronic discoid lupus erythematosus (CDLE) is characterized by well-defined 
erythematous, infiltrated, scaly patches. It is the most common form of cutaneous 
lupus erythematosus and restricted to the skin, mostly in the facial area. As lesional 
skin heals with scarring, patients are frequently offered camouflage therapy for the 
residual plaques. Because of its chronicity, CDLE severely affects quality of life.1-3 
Current treatment options include topical and systemic glucocorticosteroids,4-6 
sunscreens,7 antimalarial agents,8,9 retinoids,10,11 dapsone,12 methotrexate,13 
thalidomide,14 immunoglobulins,15 azathioprine,16 and cyclophosphamide.17 
Occasionally, beneficial effects of topical immunomodulators,18,19 biologicals,20,21 
cyclosporin,22 immunoglobulins,23 mycophenolate mofetil,24 rituximab,25 and anti-
tumor necrosis factor alfa agents26 have been reported. When a lack of efficacy or 
adverse events is experienced,physical and surgical therapies including cryotherapy, 
dermabrasion, and laser treatment have been tried. Few controlled prospective 
studies have been performed.
Laser treatment for CDLE was reported for the first time in 1986 by Henderson 
and Odom.27 One patient was treated with a carbon-dioxide laser and dramatic 
improvement was observed. Unfortunately, hypopigmentation and reactivation of 
CDLE in the treated areas were reported as side effects. In 1988, Zachariae et al.28 
treated 5 patients with CDLE with an argon laser, with significant blanching of the 
lesion although scarring and hypopigmentation were reported after treatment.
Treatment with the pulsed dye laser (PDL) was for the first time described in 1996 by 
Nuñez et al.29 Telangiectatic chronic erythema was treated in 4 patients with systemic 
lupus erythematosus by PDL. Treatment of a CDLE lesion with PDL was first reported 
in 1997 by Maushagen-Schnaas and Raulin.30 They described total clearance in one 
patient with CDLE and one with cutaneous lesions in systemic lupus erythematosus. 
In a retrospective study, Raulin et al.31 reported average clearance of about 70% in 10 
patients with CDLE and two with systemic lupus erythematosus in combination with 
discoid lesions after treatment with PDL. Only in two patients was hyperpigmentation 
observed. A similar retrospective study in which 14 patients were treated reported a 
clearance rate of 60%.32
To examine the efficacy of the PDL in the treatment of CDLE we designed a prospective 
open label study in which patients with CDLE were treated with a single laser device 
and with consistent laser parameters in a fixed treatment schedule. Clinical outcomes 
were measured by means of a well-validated scoring system.33-35
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METHODS
Patients
Patients with histologically confirmed CDLE who visited our Department of 
Dermatology from January 1, 2006, through October 31, 2006, were contacted by 
postal mail. To be eligible for the study, patients had to have at least one active 
CDLE lesion, despite the treatment with at least one standard therapy (eg, topical 
or systemic steroids, antimalarial drugs). All patients were allowed to continue 
systemic medication for CDLE, provided that this was not started or altered in the 
past 6 months (table 1). For topical treatment a wash-out period of 2 weeks was 
set. Exclusion criteria were: age younger than 18 years, pregnancy, lactation, and a 
history of photosensitivity. This study was approved by the medical ethics committee. 
Written informed consent was obtained from all patients.
Study design
At baseline one prominent CDLE lesion was selected as the target lesion and prepared 
for laser treatment. Two weeks before the start of the study, petroleum jelly was 
prescribed for all patients to standardize and optimize the pretreatment situation. 
If a lesion still showed scaling at the treatment session, arachis oil was applied to 
reduce the amount of scattering. The whole lesion was then treated with the PDL 
(Photogenica V laser, Cynosure, Chelmsfort, CA). Comparing all previous studies 
with different fluences, spot sizes, and time intervals between two treatments, the 
best results were achieved with a fluence of 5.5 J/cm2, a spot size with a diameter 
of 7 mm, and a treatment interval of 6 weeks.31 These laser parameters were used 
as standard treatment for all included patients. A pulse duration of 0.45 ms and a 
wavelength of 585 nm was constantly used, with one pass and an overlap of 10% 
to 20% per shot. During and shortly after laser treatment a cooling device (Cryo 5, 
Zimmer Electromedizin, Neu-Ulm, Germany) was used to reduce pain. If necessary, a 
second and third treatment was performed 6 and 12 weeks after the initial treatment, 
respectively. After the treatment period of maximal 12 weeks all patient entered a 
6-week follow-up period.
Clinical assessments
Clinical efficacy was assessed at baseline, after 6 and 12 weeks, and at the end of the 
6-week follow-up period using the recently validated Cutaneous Lupus Erythematosus 
Disease Area and Severity Index (CLASI).33-35 In brief, this instrument has separate 
scores for activity and damage of cutaneous lupus erythematosus lesions at 13 
different anatomic sites.
As one single CDLE lesion was assessed, which in almost all patients was located on the 
face, measuring the area of involvement was not relevant. Hence, a ‘‘limited’’ CLASI 
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scoring system was used, subdivided into an ‘‘active’’ and ‘‘damage’’ component. 
The limited active CLASI for just one target lesion included the degree of erythema 
(ranging from 0 = absent to 3 = dark red/purple) and scaling/hypertrophy (ranging 
from 0 = absent to 2 = verrucous/hypertrophic). The addition of these scores resulted 
in a total limited active CLASI score of the concerning lesion, ranging from 0 to 5. The 
limited damage CLASI was determined by measuring the presence of dyspigmentation 
(0 = absent or 1 = present) and scarring/atrophy/panniculitis (ranging from 0 = absent 
to 2 = severely atrophic scarring or panniculitis). The addition of both resulted in 
a maximum damage score of 3. The total limited CLASI reflected the sum of both 
active and damage CLASI, resulting in a score ranging from 0 to 8. All patients were 
evaluated by the same investigator at baseline and at subsequent visits.
Adverse events were recorded and patients reported pain and the cosmetic result on 
a visual analog scale (VAS). VAS scores were assessed after every PDL treatment and 
at follow-up. A score of 0 represented a total absence of pain and a cosmetically fully 
unsatisfactory result after treatment, whereas 10 represented maximal pain and a 
cosmetically excellent result after all treatments, respectively. 
Photographic evaluation
At every visit clinical photographs of the target lesions were made. Pretreatment 
and posttreatment photographs were evaluated by two additional independent 
dermatologists using the CLASI.
Statistical analysis
All analyses were carried out using statistical software (Statistica, Version 6.0, Statsoft 
Pacific, Melbourne, Australia). One-way analyses of variance were performed to 
study the clinical scores and their changes over time. If significant, Duncan’s post 
hoc comparison test was carried out. Interindividual correlation was determined by 
measuring Pearson correlation coefficient r. A p value of less than 0.05 represented 
the presence of a statistically significant difference.
RESuLTS
Patient characteristics
Twelve patients (5 men and 7 women) with mean age of 52.8 ± 2.8 (mean ± SEM) 
years were included. The mean duration of CDLE lesions was 11.2 ± 2.1 years. The 
number of active lesions ranged from one to nine. Ten of the treated lesions were 
located on the head, whereas one lesion was located on a left arm and one on a back, 
respectively. Patient characteristics are detailed in table 1.
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Table 1. Patient characteristics and treatment outcomes CLASI, cutaneous lupus erythematosus 
disease area and severity index; F, female; M, male; od, once daily.
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Active CLASI
Most patients showed a significant improvement of the treated lesion resulting in a 
decrease of the limited active CLASI (mean ± SEM). At baseline the limited CLASI was 
4.4 ± 0.2. Six weeks after the initial treatment the CLASI declined to 2.2 ± 0.4 (p =.0002). 
At week 12 and after a 6-week follow-up period, CLASI was 1.9 ± 0.4 and 1.3 ± 0.3, 
respectively (p <.0001) (figure 1A). The separate score for erythema and desquamation 
significantly reduced from 2.9 ± 0.1 to 0.9 ± 0.2 (p <.0001) and from 1.5 ± 0.2 to 0.4 ± 
0.2 (p =.007), respectively.
Damage CLASI
In contrast, the damage CLASI neither showed any significant improvement during 
nor any worsening after 6 weeks, after 12 weeks, and at follow-up. Damage CLASI 
was 1.5 ± 0.3 at baseline and 1.2 ± 0.3 at the end of the study. After follow-up the 
score was 1.4 ± 0.3 (p =.74) (figure 1B).
Total CLASI
Despite the damage CLASI not being affected, the total CLASI (active + damage CLASI) 
yielded a highly significant amelioration: 5.9 ± 0.3 at baseline to 3.1 ± 0.5 directly 
after treatment (p =.0001) and 2.8 ± 0.5 after follow-up (p <.0001), respectively 
(figure 1C).
Interobserver correlation
The active CLASI correlated very well with the scores derived from two blinded 
separate observers. Photographs were scored and yielded a correlation of r = 0.87 
and r = 0.89 (both p <.05) for the two independent observers as compared with the 
initial clinical scores, respectively. The two photograph observers intercorrelated well 
with r = 0.96 (p <.05).
Adverse events and cosmetic result
Patients reported minimal pain. The overall pain score, as measured on a 0-to-10 
VAS, was only 2.4 ± 0.5 (mean ± SEM). Only one patient (8%) developed slight 
Figure 1. Active (A), damage (B) and total (C) Cutaneous Lupus Erythematosus Disease Area 
and Severity Index (CLASI) at baseline, week 6, week 12, and after 6-week follow-up (mean ± 
SEM). N.S., Not significant. *Statistically significant compared with baseline.
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hyperpigmentation after PDL treatment (figure 2). However, the patient-rated 
overall cosmetic result, as measured on a 0-to-10 VAS, was a fair 6.9 ± 0.5 (mean 
± SEM).
DISCuSSION
Treatment of CDLE lesions with a PDL showed promising results in the case reports and 
retrospective studies described in our introduction.27-32 In these studies the number 
of treatments varied from one single treatment up to 10. There was also a wide 
variation in laser parameters such as spot size (diameter 3-7 mm), energy fluence 
(3-13 J/cm2), and pulse duration (0.3-0.45 ms). In one study, different laser systems 
were used.32 The results were obtained by determining the so-called clearance rate 
from clinical photographs taken before and after treatment. This method, however, 
is not a validated measurement instrument for CDLE lesions.
In this study, a prospective design was chosen to treat CDLE lesions with PDL, with 
a fixed treatment schedule and validated measurements (CLASI).33-35 A significant 
decline in active CLASI was observed during and after treatment. Separate individual 
scores for erythema and scale/hypertrophy significantly declined 6 weeks after 
treatment. On the other hand, scores for dyspigmentation and scarring/atrophy/
panniculitis (damage CLASI) did not show any significant improvement. The observed 
clinical improvement was confirmed by assessment of photographs taken before and 
after treatment by two independent observers. The treatment was well tolerated 
Figure 2. Chronic discoid lupus erythematosus lesion of patient before (A) and after (B) pulsed 
dye laser treatment, showing slight hyperpigmentation.
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and no serious side effects were noted. Only minimal pain was reported and the 
patient-rated overall cosmetic result was fine. A clinical photograph before and after 
6 weeks of treatment is depicted in figure 3. At this time, no scarring or relapses have 
been observed in our patients.
As expected, the damage CLASI was unaffected after treatment. This is well 
explained by the fact that the suggested working mechanism of the PDL (selective 
photothermolysis) results in a selective destruction of the cutaneous microvasculature. 
This may modulate the inflammatory network leading to regression of concerning 
CDLE lesions.36 Therefore, PDL treatment may affect the active CDLE lesion, but not, 
or only to a lesser extent, the damage components. Serial skin biopsy studies may 
shed light on the effects of PDL treatment on the pathophysiology of CDLE lesions.
Correlations between the scored CLASI by 3 independent observers were 0.87 and 
0.89, which is exceptionally high. This means that both the clinical assessment and 
the assessment of the photograph taken from the target lesion are interchangeable.
Importantly, this study offers 3 relevant novelties. First, standardized laser parameters 
of a single laser device for the treatment of one single stable CDLE lesion were used. 
These standardized parameters induced excellent clinical results; therefore, individual 
adjustments do not seem obligatory for good clinical effects. Also, if necessary, the 
same interval between the treatments was maintained. Second, a recently validated 
measurement instrument for clinical trials on cutaneous lupus erythematodes was 
used (CLASI). This scoring method measures both severity and area involvement of 
cutaneous lupus erythematodes. Because we treated only one single CDLE lesion, we 
did not use the area involvement component, and showed that this scoring method 
is applicable for the follow-up of severity of one single CDLE lesion. This application 
can be used in the future for evaluation of new topical or physical treatments, 
where multiple lesions and one target lesion is treated. Third, clinical improvement 
was confirmed by two additional independent dermatologists, by examining the 
photographs taken before and after treatment.
Figure 3. Clinical photograph of target chronic discoid lupus erythematosus lesion of patient 
12, before (A) and after (B) pulsed dye laser treatment follow-up.
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Limitations of this study are the relatively small patient group and the short follow-
up period. It would be worthwhile to evaluate the effect of PDL in a larger group of 
patients. Nevertheless, significant clinical improvements were detected; hence PDL 
may be an important addition to the therapeutic armamentarium for the treatment 
of CDLE. Future studies can be conducted, varying the parameters (eg, pulse duration 
and fluence), which may result in even more efficacious treatment with fewer side 
effects, such as hyperpigmentation.
In conclusion, PDL treatment is an effective and safe therapy for patients with 
refractory CDLE. PDL treatment may be considered for the treatment of stable, 
solitary, active CDLE lesions, when topical and/or systemic therapies have failed or 
are contraindicated.
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ABSTRACT
Background: The position of the pulsed dye laser (PDL) in the treatment of 
inflammatory skin diseases is still unclear. Evidence based recommendations are 
lacking.
Objectives: We sought to systematically review all available literature concerning 
PDL treatment for inflammatory skin diseases and to propose a recommendation.
Methods: The authors searched for publications dated between January 1992 and 
August 2011 in the database Pub Med. All studies reporting on PDL treatment for an 
inflammatory skin disease were obtained and a level of evidence was determined.
Results: Literature search revealed 52 articles which could be included in this study. 
The inflammatory skin diseases treated with PDL consisted of: psoriasis, acne 
vulgaris, lupus erythematosus, granuloma faciale, sarcoidosis, eczematous lesions, 
lichen sclerosis, granuloma anulare, Jessner lymphocytic infiltration of the skin, 
reticular erythematous mucinosis and papulopustular rosacea. The efficacy of PDL 
laser treatment for these inflammatory skin diseases was described and evaluated. 
Limitations: Most conclusions formulated are not based on randomized controlled 
trials.
Conclusions: PDL treatment can be recommended as an effective and safe treatment 
for localized plaque psoriasis, as well as for acne vulgaris (recommendation grade 
B). For all other described inflammatory skin diseases PDL seems to be promising, 
although the level of recommendation did not exceed level C.
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The efficacy of pulsed dye laser treatment for 
inflammatory skin diseases: a systematic review
INTRODuCTION
The flash lamp pumped pulsed dye laser (PDL) was the first laser specifically 
developed for the treatment of vascular lesions. The mode of action of the PDL 
is based on the principle of selective photothermolysis,1 a targeted damaging of 
specific structures in the skin without damaging the surrounding area and by direct 
cutaneous immunological activation.2,3 Omi et al.2 have shown acute inflammatory 
changes (neutophils, monocytes and mast cells) three hours after laser treatment and 
four weeks later many lymphocytes and fibroblasts were observed, still increasing in 
week five, whereas the capillaries showed an almost normal structure at week two.
The current PDL is able to vary the different parameters such as the spot size (up to 12 
mm), the pulse duration (ranging from 0.35 to 40 ms) and the energy fluence, which 
is increased in recent years due to the development of protective cooling systems.4 
The most frequently used wavelengths are 585 and 595 nm allowing the penetration 
depth to a maximum of 1.5 mm. So, the fields of application are limited to superficial 
structures. Side effects during and after treatment with PDL are dependent of the 
chosen parameters, location and skin type. They include erythema, purpura, edema, 
blistering, crusting, pigmentary changes and rarely scarring.5
Today, the PDL is considered the laser of choice for most congenital and acquired 
vascular lesions.6-8 In addition, it is used for the treatment of many other non-vascular 
or vascular dependent indications, like viral infections9,10, scars11 and stretch marks.12 
In 1992 Hacker et al. described for the first time the treatment of an inflammatory 
skin disease, psoriasis, with the pulsed dye laser.13
In order to examine the position of the PDL for the treatment of inflammatory skin 
diseases, we reviewed the current literature and provided updated information on 
the treatment of inflammatory skin diseases with the PDL.
METHODS
The focus of attention was the use of PDL in patients with inflammatory skin diseases. 
The authors searched for peer reviewed publications dated between January 1st 
1992 and August 31th 2011 in the computerized bibliographic database Pub Med. 
Selected languages were limited to English, German and Dutch. The key terms used 
were pulsed dye laser and pulsed dye lasers. The term ”inflammatory skin diseases” 
includes an extensive range of different diagnoses. Therefore the whole literature 
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on PDL was systematically scanned by a dermatologist, to be sure that all possible 
inflammatory skin diseases were found. Full details upon the search strategy are 
available upon request.
Exclusion criteria were: treatment of lesions other than inflammatory skin diseases, 
the use of other laser systems than the PDL and the use of concomitant local therapies, 
except for pre-treatment with keratinolytics in order to reduce scale and enhance 
PDL penetration. The use of concomitant systemic therapy was allowed, if this was 
not started or altered more than six weeks prior to the study onset or during the 
study itself. Outcome measures depended on the investigated skin disease. Because 
the available literature about PDL for inflammatory skin diseases is limited, all found 
articles were reviewed, including case-reports, case-series, retrospective studies, 
open-label trials, and randomized controlled trials. The bibliographies of all articles 
identified were checked for additional relevant articles that were not identified in the 
Pub Med search. After the initial search was preformed, all abstracts were screened 
for suitability for inclusion. Full text of the suitable abstracts were obtained. Articles 
were assigned a level of evidence (LOE) and afterwards graded according to the 
“Oxford Centre for Evidence-based Medicine Levels of Evidence”14 (table 1 and 2) by 
three dermatologist.
RESuLTS
Trial flow
In total 2215 articles regarding pulsed dye laser were identified. After screening of 
titles, abstracts, and full text articles if applicable, fifty-two of these articles were 
suitable to be used in the review. The publications of the inflammatory skin diseases 
treated with PDL consisted of: psoriasis (13), acne vulgaris (9), lupus erythematosus 
Chapter 4
1a Systematic review of RCTs
1b Individual RCT
2a Systematic review of cohort studies
2b Individual cohort study (including low-quality RCT)
3a Systematic review of case control studies
3b Individual case control study
4 Case series
5 Case reports, expert opinion
Table 1. Level of evindence.
RTC, randomized controlled trial; Data from the Oxford Center for Evidence-based Medicine 
Levels of Evidence.15
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(including systemic lupus erythematosus, chronic discoid lupus erythematosus and 
subacute cutaneous lupus erythematosus) (8) granuloma faciale (7), sarcoidosis (5), 
chronic eczema (1), lichen sclerosis (3) granuloma anulare (2), Jessner lymphocytic 
infiltration of the skin (1), reticular erythematous mucinosis (1) and papulopustular 
rosacea (2). All results are shown in table 3.
Psoriasis
Literature search revealed eleven articles describing PDL treatment for localized 
plaque type psoriasis 19,23 localized, chronic stable plaque psoriasis15,17,18,20 and localized 
recalcitrant plaque psoriasis13,16,21,22,24. In most studies PDL treatment was limited to 
one single or a few of lesions. Two articles described the treatment of nail psoriasis.25,26 
Outcome measures included clinical scores as (modified) Psoriasis Area and Severity 
Index (PASI), psoriasis severity index (PSI), Physician’s Global Assessment (PGA)30-31, 
total plaque severity score for erythema, scaling and thickness, nail psoriasis severity 
index (NAPSI)32, and more subjective parameters such as percentage of clearance 
obtained from pictures taken before and after treatment. 
Taibjee et al19 (LOE 2b) published a within-patient controlled prospective trial of 
treatment of localized plaque psoriasis in 22 patients. Every patient received three 
different treatments, applicated to three different plaques: PDL treatment with 
salicylic acid (SA) pretreatment, excimer laser twice weekly and SA alone. One plaque 
was left untreated to serve as control side. The PDL treated lesions showed complete 
clearance in 6 patients (27%) and improvement in 15 patients (68%). Clinical response 
to treatment was significantly greater for PDL than for both SA alone as untreated 
control. The psoriasis severity index (PSI) showed an significant improvement of 
PDL treated lesions compared to untreated lesions and there was an improvement 
compared to SA treated lesions. A subset of patients responded better on the PDL, 
although the excimer laser appears to be on average more efficacious. 
De Leeuw et al.23 (LOE 2b) preformed a single-blind, prospective paired randomized 
controlled study. In 27 patients four similar psoriasis lesions were divided into two 
halves and treated with PDL vs UVB(1), UVB vs no treatment (2), PDL vs no treatment (3) 
and PDL+UVB (4). The Physician’s Global Assessment (PGA) score showed a significant 
Table 2. Grades of recommendation.
A Studies with consistent LOE 1a and/or 1b
B Studies with consistent LOE 2a, 2b, 3a, or 3b;or extrapolations from studies with 
LOE 1a or 1b
C Studies with LOE 4 or extrapolations from studies with LOE 2a, 2b, 3a, or 3b
D Studies with LOE 5 or troubling inconsistent or inconclusive studies of any level
LOE, level of evidence; Data from the Oxford Center for Evidence-based Medicine Levels of 
Evidence.15
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improvement of the psoriasis lesions after both PDL treatment and UVB treatment. 
No significant differences were noted between the therapies. Hacker et al.13 (LOE3b) 
treated 20 patients using fluences of 5, 7, and 9 J/cm2 in three quadrants within one 
lesion; leaving one quadrant as a control side. In 11 of 19 patients clinical improvement 
was seen after one session in the area treated with 9 J/cm2, no improvement was 
seen in the other areas. Katugampola et al.15 (LOE3b) treated 8 patients with chronic 
symmetrical plaque psoriasis on one side, using the other side as a control side. 
Complete clearance was seen in one patient and a reduction of more than 50 % was 
seen in five patients after three PDL treatments. Another study16 (LOE3b) including 
10 patients, showed a significant decline of psoriasis severity score in 6 patients and 
minimal advantage in 1 patient after PDL treatment. Zelickson et al.17 (LOE 3b) achieved 
significant clearance in two to five sessions: In 13 patients one single psoriasis plaque 
was divided in two and treated unilaterally, leaving the other side as a control side. In 
another 23 patients the plaque was divided in four quadrants. Different pulse durations 
(0.45 and 1.5 ms), triamcinolone acetonide 0.1% ointment and an emollients, were 
used in the separate quadrants. Significant clinical improvement was seen after PDL. 
Bjerring et al.18 (LOE 4) compared one PDL treatment with dermabrasion in eleven 
patients. The PDL treated lesions showed a complete response in three patients and 
a partial response in six patients. Two studies20,22 (LOE 3b) compared PDL treatment 
with an active comparator and both studies showed significant reduction of psoriasis 
after PDL treatment, although the effect compared to the comparator varied in both 
studies due to the difference in laser parameters and chosen active comparator. Two 
studies investigated PDL treatment in nail psoriasis25,26 (LOE 4). One study26 showed a 
significant decrease in the Nail Psoriasis Severity Index (NAPSI) score.
Conclusion:
Grade B for localized plaque psoriasis (two studies with LOE 2B19,23 and six studies 
with LOE 3B13,15-17,20,22).
PDL proved to be an effective treatment for localized psoriasis.
Grade D for nail psoriasis (two studies with LOE 425,26)
No solid conclusion could be drawn for the treatment of nail psoriasis with PDL.
Acne 
Literature search revealed nine studies on PDL treatment for acne vulgaris.34-42 
Outcome measures included the Leeds grading system, revised Leeds grading system, 
acne lesions counting count and percentage of clearance scored on pre and post 
treatment pictures.49-52 
Seaton et al.34(LOE 1b) performed a randomized double-blind study in 41 patients 
with mild-to-moderate facial acne. Twelve weeks after a single PDL treatment, with 
two different fluences given randomly at each side of the midline, they reported 
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clinically and statistically significant reduction in acne lesions on both sides of the face. 
Orringer et al.35 (LOE 1b) did a single-blind split-face RCT in 26 patients. At 12 weeks 
changes in lesions count were not significantly different for treated vs. non-treated 
sites. A trend towards improvement in inflammatory acne was described. Jasim et 
al.36 (LOE3b) did a split-face study in 10 patients, in which one half was treated with 
PDL and the untreated site served as a control side. 50% had visible improvement 
in their acne on the treated site. Another study41 (LOE 3b) compared PDL treatment 
with a regular acne treatments. One group of fifteen patients was treated with PDL, 
and compared with two groups who received regular topical treatments (topical 
vitamin A acid, benzoyl peroxide) or chemical peels (trichloroacetic acid (TCA) 25%). 
Significant decrease in all three groups was seen, although in the follow-up period 
remission was significantly higher in the PDL group. PDL treatment was also compared 
to other, less established, treatments for acne38-40,42 (LOE 4). 15 patients treated in a 
split face study with long-pulsed PDL in comparison to long-pulsed dye laser assisted 
photodynamic therapy with methylaminolevulinic acid (MAL-LPDL)38 showed a 
reduction for both treatments. Non-inflammatory lesions reduced similar, whereas 
inflammatory lesions were more reduced on the MAL-LPDL site. In comparison with 
light emitting diode (LED) and intense pulsed light source (IPL)39 PDL achieved more 
than 90 % clearance after 4.1 sessions, compared to 6.0 for IPL and 10.0 for LED. 
In a comparative study with IPL42, both devices showed a significant reduction at 
week 8 compared to baseline; this reduction was significant larger for PDL compared 
to IPL treated sites. A different study40 compared PDL with combined 585/1064-nm 
laser treatment and found a significant reduction for both inflammatory and non-
inflammatory lesions, after both treatments. 
Conclusion:
Grade B for acne vulgaris (one study with LOE 1b34 and two studies with LOE 
3B36,41)
PDL seems to be an effective treatment for acne vulgaris.
Chronic discoid lupus erythematodes (CDLE), in systemic lupus 
erythematodes (SLE), subacute cutaneous lupus erythematodes 
(SCLE) and lupus tumidus (LT)
PDL treatment was given for CDLE lesions (27 patients),55,56,59,60 for teleangiectasias 
and erythematous patches in patients with SLE (12 patients),53,54,55,56,58 for SCLE lesions 
(3 patients)56,57,60 and for LT (2 patients).60 Outcome measures included estimated 
clearance rate (ECR) and modified cutaneous lupus erythematodes disease area and 
severity index (CLASI). 61
CDLE
Raulin et al.56 (LOE 4) described the treatment of 8 CDLE patients in a retrospective 
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study and showed an average clearance rate of 57.5 % after an average of 4 treatments 
(ranging from 1-6) One study59 described a significant improvement of CDLE lesions 
after PDL treatment. A recently published study60 confirmed these findings.57 
Conclusion:
Grade C for CDLE (3 publications with LOE 456,59,60).
PDL seems an effective therapeutic option for localized CDLE.
SLE
Nunez et al.54 (LOE 4) described for the first time the treatment of four SLE patients 
with PDL and found a clearance rate of 75%. Similar results were founded by 
Baniandres et al.58 (LOE 4) describing an average clearance of 68.0% (range 50-
80%) after 4.2 (range 1-10) treatments in five patient. Another case serie56 (LOE 4) 
confirmed these findings. One case report55 (LOE 5) described complete clearance 
after three PDL treatments.
Conclusion:
Grade C for SLE (3 publications with LOE 454,56,58).
PDL seems an effective therapeutic option for SLE.
SCLE and lupus tumidus
Three patients with SCLE (LOE 5)56.57,60 showed marked improvement after PDL 
treatment and two patients with lupus tumidus (LOE 5)60 showed a significant 
reduction of erythema and scaling after PDL treatment.
Conclusion:
Grade D for the treatment of SCLE (3 patients) and lupus tumidus (2 patients).
PDL in SCLE and lupus tumidus seems effective in a small number of patients 
Pulsed dye laser in granuloma faciale
The treatment of granuloma faciale (GF) with PDL was described in five case reports62-68 
and two case series.66,67 
Cheung et al.66 (LOE 4) reported four cases of GF treated with PDL. Two patients 
achieved a significant cosmetic improvement of their GF, whereas the GF lesions in 
the other two patients stayed unaltered. No complications were recorded. A recently 
published case serie67 (LOE 4) of four patients described complete flattening and 
bleaching of all treated lesions in three patients, whereas one treated lesion remained 
bright red-brown. Four case reports62-65 (LOE 5) described a complete remission of 
GF after pulsed dye laser treatment, whereas one case report68 (LOE 5) described a 
marked improvement.
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Conclusion:
Grade C for granuloma faciale (2 case series with LOE 466,67).
Treatment of granuloma faciale with PDL seems to be promising, but the number of 
patients is too small to draw a firm conclusion.
Pulsed dye laser in cutaneous sarcoidosis
Five case reports of PDL treatment for cutanous sardoidosis/lupus pernio69-73 were 
identified. An improvement of 75% till complete remission was described in four 
cases69,70,72,73. One case-report described a limited effect.71
Conclusion:
Grade D for cutaneous sarcoidosis (5 case reports with LOE 569-73).
PDL seems to be an effective treatment to improve cutaneous sarcoidosis lesions, 
however, a solid conclusion could not be drawn based on 5 patients.
Eczematous skin lesions
One article was found in which chronic eczema were treated with the pulsed dye 
laser. Syed et al.76 (LOE 3b) treated 12 children with localized chronic eczema with 
one cycle of PDL in a pilot study. A significant decrease in Eczema Severity Score (ESS) 
and a significant difference in eczema severity assessed by a visual analogue score 
(VAS) was found in favour of PDL. The treatment was well tolerated.
Conclusion:
Grade C for chronic eczema (one study with LOE 3b76).
PDL treatement for eczematous lesions seems to be promising. More studies with 
larger patient numbers are needed.
Pulsed dye laser in papulopustular rosacea
Two studies for papulopustular rosacea was identified. Berg et al.88 (LOE 3b) treated 14 
patients with moderate to severe papulopustular rosacea and marked telangiectases/
erythema with PDL. Ten patients finished the study. After treatment two patients 
had markedly less papulopustular lesions, three had only slight less papulopustular 
lesions, in three patients lesions were unchanged, two patients developed more 
lesions after treatment. Bernstein et al.89 (LOE 4) described significant decrease in 
rosacea in 17 patients. 
Conclusion:
Grade C for papulopustular rosacea (one study with LOE 3b88).
The use of PDL for papulopustular lesions in rosacea showed controversial results in 
one study. More studies with larger patient numbers are needed.
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Pulsed dye laser in lichen sclerosis, granuloma anulare, Jessner 
lymphocytic infiltration and reticular erythematous mucinosis 
(R.E.M.)
Three case reports were found about pulsed dye laser treatment for lichen 
sclerosus.80-82 Two case reports80-81 (LOE 5) described complete clearance of the 
treated lesions, whereas one report82 (LOE 5) described a marked improvement 
in one treated lesion, and a moderate effect in another treated lesion. Two case 
reports are described about granuloma anulare (GA).84,85 Both case reports (LOE 5) 
described an almost complete flattening and lightening of the treated lesions. One 
case report of Jessner lymphocytic infiltration of the skin.86 describes a complete 
clearance after one PDL treatment. One case serie87 reports complete clearance 
and good clinical response of R.E.M.in two patients after PDL treatment. 
Conclusion:
Grade D for lichen sclerosis (3 case reports with LOE 580-82), granuloma annulare(2 
case reports with LOE 584,85) Jessner lymphocytic infiltration (one case report with 
LOE 586) and R.E.M.(one case serie with LOE 587).
The efficacy of PDL is still unclear, due to the small number of treated patients.
DISCuSSION
Initially, the pulsed dye laser was used for the treatment of vascular indications. Two 
decades ago, the PDL treatment of a psoriasis plaque lesion14 showed promising 
results and therefore triggered the attention to optimize the treatment parameters 
for this disease and to explore pulse dye laser treatment for other inflammatory skin 
diseases. 
Literature concerning treatment efficacy and safety of pulsed dye laser for 
inflammatory skin diseases is diverse. Overall, most studies have shown limitations 
in small patient numbers, inconsistent treatment parameters and a relatively short 
follow up period. Large randomized controlled trials with consistent laser parameters, 
validated outcome measures and long follow-up period are lacking. 
Psoriasis was the most investigated inflammatory skin disease. All studies described 
the treatment of localized psoriasis, which mostly concerned chronic, stable 
plaque psoriasis, sometimes explicitly described as recalcitrant, not responding to 
conventional therapy such as potent topical steroids, UVB, PUVA and tar. The results 
of treatment with PDL on various sites of the body were highly variable, therefore no 
recommendation can be done about which anatomic site will respond best. Despite 
the currency of this skin disease, no large randomized controlled trials on the efficacy 
of PDL for psoriasis were identified. Practically, PDL treatment is limited for a few 
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psoriasis plaque lesions who are resistant to conventional therapy. According to our 
opinion, it should be considered, based on evidence, for solitary recalcitrant psoriasis 
lesions. 
Two large randomized controlled trials35,36 were preformed for acne treatment with 
PDL. The statistically significant improvement of acne lesions after PDL treatment in 
the first study, could not be confirmed by the second study, possibly due to different 
used laser parameters and different treatment regimens. Despite the positive finding 
of the first study and the promising results found in other studies, it is still unclear, 
whether PDL treatment for acne will become a standard treatment in the future. No 
large intra-patient, split-face comparative studies were done with PDL treatment in 
comparison with other well established, easy accessible treatments, so the added 
value to conventional forms of therapy is still unclear. One could hypothesize that 
it can be an alternative when topical therapies have failed or are contraindicated, 
before starting systemic therapy. Recommendation grade B was given for the PDL 
treatment of both localized psoriasis and acne vulgaris.
Evidence for all other in this review mentioned inflammatory skin diseases (SLE, 
CDLE, SCLE, granuloma faciale, cutaneous sarcoidosis, chronic eczema, lichen 
sclerosis, granuloma annulare, Jessner lymphocytic infiltration of the skin, REM and 
papulopustular rosacea) is of a low level, i.e. grade C and D. While the incidence of 
these skin diseases, except for eczematous lesions and rosacea, is quite low, it is 
unlikely that large randomized trials will be performed in the near future to position 
the PDL for these skin diseases. Despite the low recommendation level, it is still 
worth to consider treating these lesions with PDL, when topical and/or systemic 
therapies have failed or are contraindicated, while they are often located in the facial 
area/chest and can be recalcitrant to conventional therapies, therefore giving a lot of 
emotional distress. Due to the light sensitivity of some of these diseases, one should 
be extra cautious when treating these lesions with PDL. One study described the 
treatment of eczema with PDL and showed good results. This promising result should 
be further investigated, with the emphasis, like in psoriasis, on localized recalcitrant 
eczema with failure or contra-indication to topical and/or systemic therapies.
Pulsed dye laser treatment for inflammatory skin diseases has shown to be effective 
for localized psoriasis and acne vulgaris and can be recommended if conventional 
therapies have failed and/or are contraindicated. For other inflammatory skin it can 
be considered as an alternative or supplementary treatment. Long-term studies in 
large groups of patients are clearly needed.
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Author LOE Study 
type
No. of 
patients
Laser parameters Treatment parameters Location Control 
side
Pre-
treatment 
Tool 
assessment
Results Side effects
λ ø pulse 
duration
fluence No. of 
treat-
ments
Treatment 
interval
Follow-
up
Psoriasis
Hacker et al., 
1992 (13)
3b OL 19 585 5 0.45 5.0,7.0 
and 9.0 di-
vided over 4 
quadrants, 
leaving one 
quadrant 
untreated
1 _ 8 w trunk/sacral/
extremities
one quadrant in 
lesion
no E,S and T on 1-7 
scale, P
11 (57%) of 19 patients were found 
to have a clinically positive effect in 
de quadrant treated with 9.0 J/cm2. 
no complete clearance. Negliligible 
improvement in 5.0 and 7.0 quadrant.
none
Katugampola 
et al.,1994 
(15)
3b OL 8 585 5 0.45 8.5 3 2 10 m knee/elbow yes emollient E,S and T on 0-4 
scale, PASI, H
5 patients> 50% reduction of plaque 
severity score, 1 patient had complete 
clearance ; decrease of vessel diameter. 
No decernible trend in cell infiltrate 
(polymorphs and lymphocytes)
hemoragic 
crusts
Ros et 
al.,1996 (16)
3b CS 10 585 5 0.36-0.45 6.5-8.0 1-3 2-3w 2-9 w arm/leg/trunk yes emolllient  E,S and I on 0-3 
scale,P, H 
significant decline of psoriasis severity 
score in 6 patients, minimal advantage 
in 1 patient, no advantage in 3 patients. 
Epidermal thinning and regenaration 
without sings of psoriasis
hypo- and 
hyper-
pigmentation
Zelickson et 
al.,1996 (17)
3b OL 36 585 5 0.45;1.5 7.5-8.5 2-5 2-3w 4-13 m arm/trunk polysporine 
ointment, 
corticosteroid 
ointment group 
II intralesional 
and different 
pulse durations 
intralesional
no E, S, I on 0-4 scale, 
P, H
significant clinical improvement; no 
significant difference between 0.45 and 
1.5 ms; histological normalization after 
treatment
mild hyper-/
hypo-
pigmentation
Bjerring et 
al.,1997 (18)
4 CS 11 585 5 0.2 2.0-7.0 1 _ 4-9 m elbow/leg/
trunk
dermabrasion emollient ECR, P, H 3 (of 11) patients treated with laser 
showed complete remission vs 5 (of 
6) treated with dermabrasion. Partial 
response in 6 laserpatients, and 2 patients 
showed no response. Histology in one 
patient was without characteristics of 
the disease.
 slight hyper- 
and hypo-
pigmentation
Taibjee et al., 
2005 (19)
2b OL 22 595 7 1.5 10.0-12.0 2-4 4w 12 m trunk/limbs untreated 
lesions, salicylic 
acid and eximer 
laser
salicylic acid 
1week before 
every treatment
PASI, PSI, P and 
spectrophotomet-
ric intracutaneous 
analysis
6 patients showed complete clearance, 
and 15 patients showed improvement. 9 
patients had the same or better response 
compared to the excimer laser. 
hypo-
pigmentation 
and blistering
Ilknur et al., 
2006 (20)
3b CS 19 585 5 0.35 7.0-8.5 3 3w 9 w trunk/limbs salicylic acid+ 
PDL and 
salicylic acid 
and clobetasol 
proprionate
no/salicylic acid 
before every 
treatment
modified PASI, P mPASI decreased in all groups when 
compared with baseline, no statistically 
significant difference between PDL and 
PDL/salicylic acid. 
mild to 
moderate 
hyper-
pigmentation
de Leeuw 
et al., 2006 
(21)
4 CS 41 585 7 0.45 5.0-6.5 4.2 4-6w 36 m hands/feet no calcipotriol or 
salicylic acid 
before each 
treatment
ECR, P 76% good to very good improvement. 
Average duration of remission 11 months
transient 
hyper- and 
hypo-
pigmentation
Erceg et al., 
2006 (22)
3b OL 8 585 5 0.45 8.5 1-3 2w 3 m trunk/limbs vs calcipotriol/
betamethasone 
dipropionate
salicylic acid 
before initial 
treatment
E, I, S on 0-4 scale,P significant difference in SUM score in 
favour of PDL. Pain scores declined 
although not statistically significant 
hyper-
pigmentation
de Leeuw 
et al., 2009 
(23)
2b OL 27 585 7 0.45 5.5-6.5 4 3w 13 w unknown vs UVB vsPDL 
+ UVB vs no 
treatment
salicylic acid 
before each 
treatment
PGA-score significant improvement in both PDL as 
UVB treatment. No significant differences 
between PDL-UVB; No synergism of both 
therapies is observed
transient 
hyper-
pigmentation
Table 3. CLASI, cutaneous lupus erythematosus disease area and severity index61; CR, 
case report; CS, case series; E, erythema; ECR, estimated clearance rate; ESS eczema 
severity score77-79; H, histological examination; I, infiltration/induration; IPL, intense 
pulsed light source; LED, light emitting diode; m, month; NAPSI, nail psoriasis severity 
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Psoriasis
Hacker et al., 
1992 (13)
3b OL 19 585 5 0.45 5.0,7.0 
and 9.0 di-
vided over 4 
quadrants, 
leaving one 
quadrant 
untreated
1 _ 8 w trunk/sacral/
extremities
one quadrant in 
lesion
no E,S and T on 1-7 
scale, P
11 (57%) of 19 patients were found 
to have a clinically positive effect in 
de quadrant treated with 9.0 J/cm2. 
no complete clearance. Negliligible 
improvement in 5.0 and 7.0 quadrant.
none
Katugampola 
et al.,1994 
(15)
3b OL 8 585 5 0.45 8.5 3 2 10 m knee/elbow yes emollient E,S and T on 0-4 
scale, PASI, H
5 patients> 50% reduction of plaque 
severity score, 1 patient had complete 
clearance ; decrease of vessel diameter. 
No decernible trend in cell infiltrate 
(polymorphs and lymphocytes)
hemoragic 
crusts
Ros et 
al.,1996 (16)
3b CS 10 585 5 0.36-0.45 6.5-8.0 1-3 2-3w 2-9 w arm/leg/trunk yes emolllient  E,S and I on 0-3 
scale,P, H 
significant decline of psoriasis severity 
score in 6 patients, minimal advantage 
in 1 patient, no advantage in 3 patients. 
Epidermal thinning and regenaration 
without sings of psoriasis
hypo- and 
hyper-
pigmentation
Zelickson et 
al.,1996 (17)
3b OL 36 585 5 0.45;1.5 7.5-8.5 2-5 2-3w 4-13 m arm/trunk polysporine 
ointment, 
corticosteroid 
ointment group 
II intralesional 
and different 
pulse durations 
intralesional
no E, S, I on 0-4 scale, 
P, H
significant clinical improvement; no 
significant difference between 0.45 and 
1.5 ms; histological normalization after 
treatment
mild hyper-/
hypo-
pigmentation
Bjerring et 
al.,1997 (18)
4 CS 11 585 5 0.2 2.0-7.0 1 _ 4-9 m elbow/leg/
trunk
dermabrasion emollient ECR, P, H 3 (of 11) patients treated with laser 
showed complete remission vs 5 (of 
6) treated with dermabrasion. Partial 
response in 6 laserpatients, and 2 patients 
showed no response. Histology in one 
patient was without characteristics of 
the disease.
 slight hyper- 
and hypo-
pigmentation
Taibjee et al., 
2005 (19)
2b OL 22 595 7 1.5 10.0-12.0 2-4 4w 12 m trunk/limbs untreated 
lesions, salicylic 
acid and eximer 
laser
salicylic acid 
1week before 
every treatment
PASI, PSI, P and 
spectrophotomet-
ric intracutaneous 
analysis
6 patients showed complete clearance, 
and 15 patients showed improvement. 9 
patients had the same or better response 
compared to the excimer laser. 
hypo-
pigmentation 
and blistering
Ilknur et al., 
2006 (20)
3b CS 19 585 5 0.35 7.0-8.5 3 3w 9 w trunk/limbs salicylic acid+ 
PDL and 
salicylic acid 
and clobetasol 
proprionate
no/salicylic acid 
before every 
treatment
modified PASI, P mPASI decreased in all groups when 
compared with baseline, no statistically 
significant difference between PDL and 
PDL/salicylic acid. 
mild to 
moderate 
hyper-
pigmentation
de Leeuw 
et al., 2006 
(21)
4 CS 41 585 7 0.45 5.0-6.5 4.2 4-6w 36 m hands/feet no calcipotriol or 
salicylic acid 
before each 
treatment
ECR, P 76% good to very good improvement. 
Average duration of remission 11 months
transient 
hyper- and 
hypo-
pigmentation
Erceg et al., 
2006 (22)
3b OL 8 585 5 0.45 8.5 1-3 2w 3 m trunk/limbs vs calcipotriol/
betamethasone 
dipropionate
salicylic acid 
before initial 
treatment
E, I, S on 0-4 scale,P significant difference in SUM score in 
favour of PDL. Pain scores declined 
although not statistically significant 
hyper-
pigmentation
de Leeuw 
et al., 2009 
(23)
2b OL 27 585 7 0.45 5.5-6.5 4 3w 13 w unknown vs UVB vsPDL 
+ UVB vs no 
treatment
salicylic acid 
before each 
treatment
PGA-score significant improvement in both PDL as 
UVB treatment. No significant differences 
between PDL-UVB; No synergism of both 
therapies is observed
transient 
hyper-
pigmentation
index32; OL, open label trial; PASI, psoriasis area and severity index30-31; PGA-score, 
physician’s global assessment-score30-31; P, pictures before and after treatment; PSI, 
psoriasis activity and severity index; RCT, randomized controlled trial; S, scaling; SA, 
salicylic acid; T, thickness; VAS, visual analogue score; w, week; y, year. 
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Treatment 
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up
Noborio et 
al., 2009 
(24)
4 CS 11 585 10 0.45 8.0 4.5 (1-9) 4w 1 m trunk/arm no 7% lidocaine 
creme
E, S, T on 0-4 
scale, H
significant decline in plaque severity 
score; significant decrease in microvessel 
count; downward trend in mean 
microvessel diameter
Fernández-
Guarino et 
al., 2009 
(25)
4 CS 14 595 7 6.0 9.0 6 4w 6 m nails methylami-
nolaevulinic 
acid and PDL
no NAPSI, P a decrease in NAPSI for both treatments; 
No statistical difference between the 
treatmetn
Oram et al., 
2010 (26)
4 CS 5 595 7 1.5 8.0-10.0 3 4w 3 m nails no no NAPSI significant decrease in NAPSI score
Acne
Seaton et al., 
2003 (34)
1b RCT, 
double 
blind
41 (36 
com-
pleted)
585 5 0.35 1.5 and 3.0 1 _ 12 w face parallel group no Leeds grading 
system (ref. 49) and 
lesions count
After 12 wks decline in acne severity 
(Leeds scale) 3.8 (SD1.5)to 1.9(1.5)in 
PDL and 3.6 (1.8)to 3.5 (1.9) in control 
group (p=0.007). Total lesions fell by 
53% in PDL and 9% in controls (p=0.023). 
Inflammatory lesions fell by 49% in 
PDL and 10 % in controls (p=0.024). No 
differences between two fluence levels.
Orringer et 
al., 2004 
(35)
1b RCT, 
single 
blind
40 (26 
com-
pleted)
585 7 0.35 3.0 1(group1); 
2(group 2)
0 (group 
1, single 
treatment), 
2 weeks 
(group 2)
12 w face yes no lesions count, P No significant differences between laser 
treated vs untreated skin for reductions 
in mean papule counts (38% vs 25% 
p=0.08), mean pustules counts (0 vs 35 %, 
p=0.12)or mean comedone counts (9%vs 
6%, p=0.63) No significant difference in 
overall acne severity between treated and 
untreated skin 
post-
inflammatory 
hyper-
pigmentation
Jasim. et al., 
2005 (36)
3b OL, 
intrapa-
tient)
10 595 10 6.0 7.0 1 _ 6 w face yes, intra 
patient
no modified Leeds 
Acne Score (ref 
50), P
Significant reduction in the Modiefied 
Leeds Acne Score from 4.1 to 2.8 (treated 
site), from 3.7 to 3.5 (untreated site) 
(p<0.05)
Harto et al., 
2007 (37)
4 OL 36 (30 
com-
pleted)
585 ? 0.35 2.5 3 4w 12 w face no no lesions count, P Inflammatory lesions: reduction of 57 % 
after 12 weeks, non-inflammatoiry le-
sions: reduction of 27% after 12 weeks.
Haedersdal 
et al., 2008 
(38)
4 intra-
patient 
com-
parative 
trial
15 (12 
com-
pleted)
595 10 10 7.5 (2 
passes)
3 2w 12 w face MAL cream on 
one side of the 
face according 
to randomisa-
tion
no lesions count, P Inflammatory lesions were reduced 
more on MAL-LPDL treated than on 
LPDLtreated sides alone (wk 4: 70% vs 
50%. P=0.03, wk12 80%vs67% p=0.04).
non inflammatory lesions reduced 
similarly. 
Erythema, 
edema and 
pustular erup-
tion from MAL 
incubation.
Sami et al., 
2008 (39)
4 com-
parative 
study
15 (30 
other pa-
tients were 
treated 
with IPL or 
LED)
585 7 0.35 3.0 4.1 face no no ECR > or = 90 %clearance of their 
inflammatoiry lesions was seen after 4.1 
+/- 1.39 sessions in the PDL group; after 
6.0 +/- 2.05 sessions in the IPL group 
and after 10.0 +/- 3.34 sessions in the 
LED group 
Jung et al., 
2009 (40)
4 Rand-
omized 
prospec-
tive, double 
blind
18 (16 
completed)
585 7 40 7.0 3 2w 12w face no, other side 
treated with 
PDL and Nd-YAG
no Cunliffe’s grading 
system (ref 52), 
lesions count, P,H
Significant reduction for inflammatory 
as well as for non-inflammatory acne 
lesions after both PDL and PDL/Nd-YAG. 
No significant difference between both 
treatments at the end of the study. Both 
treatments↓inflammation and IL-8 
expression and↑TGF-β
no significant 
adverse 
reactions
Leheta et al., 
2009 (41)
3b randomized 
trial
15 (30 
treated 
with topical 
treatment 
or chemical 
peels)
585 7 0.35 3.0 6 2w 8m face no; other pa-
tients received 
either topical 
treatment 
no Leeds acne scoring 
system,P
Significant decrease in all three groups, 
no significant difference was detected 
between the three groups; remission in 
the follow-up period was significantly 
higher in the PDL group
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Noborio et 
al., 2009 
(24)
4 CS 11 585 10 0.45 8.0 4.5 (1-9) 4w 1 m trunk/arm no 7% lidocaine 
creme
E, S, T on 0-4 
scale, H
significant decline in plaque severity 
score; significant decrease in microvessel 
count; downward trend in mean 
microvessel diameter
Fernández-
Guarino et 
al., 2009 
(25)
4 CS 14 595 7 6.0 9.0 6 4w 6 m nails methylami-
nolaevulinic 
acid and PDL
no NAPSI, P a decrease in NAPSI for both treatments; 
No statistical difference between the 
treatmetn
Oram et al., 
2010 (26)
4 CS 5 595 7 1.5 8.0-10.0 3 4w 3 m nails no no NAPSI significant decrease in NAPSI score
Acne
Seaton et al., 
2003 (34)
1b RCT, 
double 
blind
41 (36 
com-
pleted)
585 5 0.35 1.5 and 3.0 1 _ 12 w face parallel group no Leeds grading 
system (ref. 49) and 
lesions count
After 12 wks decline in acne severity 
(Leeds scale) 3.8 (SD1.5)to 1.9(1.5)in 
PDL and 3.6 (1.8)to 3.5 (1.9) in control 
group (p=0.007). Total lesions fell by 
53% in PDL and 9% in controls (p=0.023). 
Inflammatory lesions fell by 49% in 
PDL and 10 % in controls (p=0.024). No 
differences between two fluence levels.
Orringer et 
al., 2004 
(35)
1b RCT, 
single 
blind
40 (26 
com-
pleted)
585 7 0.35 3.0 1(group1); 
2(group 2)
0 (group 
1, single 
treatment), 
2 weeks 
(group 2)
12 w face yes no lesions count, P No significant differences between laser 
treated vs untreated skin for reductions 
in mean papule counts (38% vs 25% 
p=0.08), mean pustules counts (0 vs 35 %, 
p=0.12)or mean comedone counts (9%vs 
6%, p=0.63) No significant difference in 
overall acne severity between treated and 
untreated skin 
post-
inflammatory 
hyper-
pigmentation
Jasim. et al., 
2005 (36)
3b OL, 
intrapa-
tient)
10 595 10 6.0 7.0 1 _ 6 w face yes, intra 
patient
no modified Leeds 
Acne Score (ref 
50), P
Significant reduction in the Modiefied 
Leeds Acne Score from 4.1 to 2.8 (treated 
site), from 3.7 to 3.5 (untreated site) 
(p<0.05)
Harto et al., 
2007 (37)
4 OL 36 (30 
com-
pleted)
585 ? 0.35 2.5 3 4w 12 w face no no lesions count, P Inflammatory lesions: reduction of 57 % 
after 12 weeks, non-inflammatoiry le-
sions: reduction of 27% after 12 weeks.
Haedersdal 
et al., 2008 
(38)
4 intra-
patient 
com-
parative 
trial
15 (12 
com-
pleted)
595 10 10 7.5 (2 
passes)
3 2w 12 w face MAL cream on 
one side of the 
face according 
to randomisa-
tion
no lesions count, P Inflammatory lesions were reduced 
more on MAL-LPDL treated than on 
LPDLtreated sides alone (wk 4: 70% vs 
50%. P=0.03, wk12 80%vs67% p=0.04).
non inflammatory lesions reduced 
similarly. 
Erythema, 
edema and 
pustular erup-
tion from MAL 
incubation.
Sami et al., 
2008 (39)
4 com-
parative 
study
15 (30 
other pa-
tients were 
treated 
with IPL or 
LED)
585 7 0.35 3.0 4.1 face no no ECR > or = 90 %clearance of their 
inflammatoiry lesions was seen after 4.1 
+/- 1.39 sessions in the PDL group; after 
6.0 +/- 2.05 sessions in the IPL group 
and after 10.0 +/- 3.34 sessions in the 
LED group 
Jung et al., 
2009 (40)
4 Rand-
omized 
prospec-
tive, double 
blind
18 (16 
completed)
585 7 40 7.0 3 2w 12w face no, other side 
treated with 
PDL and Nd-YAG
no Cunliffe’s grading 
system (ref 52), 
lesions count, P,H
Significant reduction for inflammatory 
as well as for non-inflammatory acne 
lesions after both PDL and PDL/Nd-YAG. 
No significant difference between both 
treatments at the end of the study. Both 
treatments↓inflammation and IL-8 
expression and↑TGF-β
no significant 
adverse 
reactions
Leheta et al., 
2009 (41)
3b randomized 
trial
15 (30 
treated 
with topical 
treatment 
or chemical 
peels)
585 7 0.35 3.0 6 2w 8m face no; other pa-
tients received 
either topical 
treatment 
no Leeds acne scoring 
system,P
Significant decrease in all three groups, 
no significant difference was detected 
between the three groups; remission in 
the follow-up period was significantly 
higher in the PDL group
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Choi et al., 
2009 (42)
4 split-face, 
single blind, 
RCT
20 585 10 40 8.0-10.0 4 2w 12w face no, IPL treat-
ment on other 
half)
no Cunliffe’s grading 
system, lesions 
count, P,H
after 8 weeks inflammatoiry lesions were 
reduced to 14 % of baseline (vs 45 % in 
the IPL group); the non-inflammatoiry 
were reduced to 41% (PDL) and 57 % 
(IPL).Reduction of the acne grade from 
2.5 to 1.0 (PDL) and from 2.5 to 1.2 (IPL). 
Patient satisfaction scores was 5.2 (PDL) 
and 4.7 (IPL). amelioration in inflamma-
tory reactions and an increase in TGF-β 
expression after both treatments more 
prominent for PDL site
Lupus erythematodes
Nunez et al., 
1995 (53)
5 CR 1(SLE) 585 5 0.45 7.25-8.75 5 16 face no no ECR exellent
Nunez et al., 
1995 (54)
4 CS 4(SLE) 585 5 0.45 6.75-8.75 3-6 16 face no no ECR, P, H 75 % clearance of the lesions; reduction in 
diameter of blood vessels. No changes in 
dermal infiltrate and direct immun-
ofluorescence. (CR (ref 53) is included 
in this CS)
slight transient 
hyper-
pigmentation in 
one patient
Maushagen-
Schnaas et 
al., 1997 
(55)
5 CR 1 (CDLE) 585 7; 10 5.5 and 3.5 2 4w 12m cheek/back no no ECR complete clearance
5 CR 1 (SLE) 585 7; 10 5.5-6.0 and 
3.2
3 1-5m 12m no no ECR, H complete clearance, decrease in IgG en C3 slight hyper-
pigmentation
Raulin et al., 
1999 (56)
4 CS 8 (CDLE) 585 5;7;10 0.45 3.4-7.0 3.8(1-9) 2w-5m 14.3 
(5-32m)
face/thrunk no no ECR, P median 57.5 % clearance (varying from no 
visible improvement till total clearance) 
1 patient was excluded due to concom-
mitant local treatment
transient 
hyper-
pigmentation 
in 2 patients
5 CR 1 (SCLE) 585 7 0.45 3.0-7.0 6 4w inter-
rupted
no no ECR, P clearance rate 50%
4 CS 2 (SLE) 585 5;7 0.45 5.5-6.5 7.5 (7-8) 1-5m 3-6m no no ECR, P 75% clearance (70 and 80 %)
Gupta et al., 
1999 (57)
5 CR 1 (SCLE) 585 5 0.45 5.3 4 1m face, neck and 
arms
no no ECR, P marked improvement
Baniandres 
et al., 2003 
(58)
4 CS 5 (SLE) 585/ 
595
5;7 0.45-10.0 5.0-8
.75/6.0-12.0
3.8 (1-10) 2.8-12.0m 2.7y (8m-
6y)
face, cheeks 
and thrunk
no no ECR, P, H average clearance rate 68.0 % (range 
50-80%);histology for lupus negative, IFD 
similar to pre-treatment biopsy. One pa-
tient with SLE, seven with CDLE and one 
with lupus tumidus were excluded due to 
concommitant local treatment
one patient 
developed 
hyper- and 
hypo-
pigmentation
Erceg et al., 
2009 (59)
4 OL 12 (CDLE) 585 7 0.45 5.5 1-3 6w 6w face, scalp, 
thrunk and 
limbs
no no modified CLASI, P Baseline CLASI was 4.4 ± 0.2 (mean ± 
SEM), reaching 1.3 ± 0.3 after follow-up 
(p<0.0001). ‘damage’ CLASI did not show 
any significant change during and after 
therapy. The observed clinical improve-
ment was confirmed by assessment 
of photographs taken before and after 
treatment by two additional independent 
observers 
one patient 
developed 
slight hyper-
pigmentation
Diez et al., 
2011 (60)
4 OL 6(CDLE) 595 7 2 11 1 _ 4w face, back, arm 
and hand
no no modified CLASI, H Significant reduction of erythema and 
scaling after treatment; significant reduc-
tion of dermal lymphocytic infiltrate and 
an important reduction of basal damage. 
ICAM-1 and VCAM-1 expression was 
reduced
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Choi et al., 
2009 (42)
4 split-face, 
single blind, 
RCT
20 585 10 40 8.0-10.0 4 2w 12w face no, IPL treat-
ment on other 
half)
no Cunliffe’s grading 
system, lesions 
count, P,H
after 8 weeks inflammatoiry lesions were 
reduced to 14 % of baseline (vs 45 % in 
the IPL group); the non-inflammatoiry 
were reduced to 41% (PDL) and 57 % 
(IPL).Reduction of the acne grade from 
2.5 to 1.0 (PDL) and from 2.5 to 1.2 (IPL). 
Patient satisfaction scores was 5.2 (PDL) 
and 4.7 (IPL). amelioration in inflamma-
tory reactions and an increase in TGF-β 
expression after both treatments more 
prominent for PDL site
Lupus erythematodes
Nunez et al., 
1995 (53)
5 CR 1(SLE) 585 5 0.45 7.25-8.75 5 16 face no no ECR exellent
Nunez et al., 
1995 (54)
4 CS 4(SLE) 585 5 0.45 6.75-8.75 3-6 16 face no no ECR, P, H 75 % clearance of the lesions; reduction in 
diameter of blood vessels. No changes in 
dermal infiltrate and direct immun-
ofluorescence. (CR (ref 53) is included 
in this CS)
slight transient 
hyper-
pigmentation in 
one patient
Maushagen-
Schnaas et 
al., 1997 
(55)
5 CR 1 (CDLE) 585 7; 10 5.5 and 3.5 2 4w 12m cheek/back no no ECR complete clearance
5 CR 1 (SLE) 585 7; 10 5.5-6.0 and 
3.2
3 1-5m 12m no no ECR, H complete clearance, decrease in IgG en C3 slight hyper-
pigmentation
Raulin et al., 
1999 (56)
4 CS 8 (CDLE) 585 5;7;10 0.45 3.4-7.0 3.8(1-9) 2w-5m 14.3 
(5-32m)
face/thrunk no no ECR, P median 57.5 % clearance (varying from no 
visible improvement till total clearance) 
1 patient was excluded due to concom-
mitant local treatment
transient 
hyper-
pigmentation 
in 2 patients
5 CR 1 (SCLE) 585 7 0.45 3.0-7.0 6 4w inter-
rupted
no no ECR, P clearance rate 50%
4 CS 2 (SLE) 585 5;7 0.45 5.5-6.5 7.5 (7-8) 1-5m 3-6m no no ECR, P 75% clearance (70 and 80 %)
Gupta et al., 
1999 (57)
5 CR 1 (SCLE) 585 5 0.45 5.3 4 1m face, neck and 
arms
no no ECR, P marked improvement
Baniandres 
et al., 2003 
(58)
4 CS 5 (SLE) 585/ 
595
5;7 0.45-10.0 5.0-8
.75/6.0-12.0
3.8 (1-10) 2.8-12.0m 2.7y (8m-
6y)
face, cheeks 
and thrunk
no no ECR, P, H average clearance rate 68.0 % (range 
50-80%);histology for lupus negative, IFD 
similar to pre-treatment biopsy. One pa-
tient with SLE, seven with CDLE and one 
with lupus tumidus were excluded due to 
concommitant local treatment
one patient 
developed 
hyper- and 
hypo-
pigmentation
Erceg et al., 
2009 (59)
4 OL 12 (CDLE) 585 7 0.45 5.5 1-3 6w 6w face, scalp, 
thrunk and 
limbs
no no modified CLASI, P Baseline CLASI was 4.4 ± 0.2 (mean ± 
SEM), reaching 1.3 ± 0.3 after follow-up 
(p<0.0001). ‘damage’ CLASI did not show 
any significant change during and after 
therapy. The observed clinical improve-
ment was confirmed by assessment 
of photographs taken before and after 
treatment by two additional independent 
observers 
one patient 
developed 
slight hyper-
pigmentation
Diez et al., 
2011 (60)
4 OL 6(CDLE) 595 7 2 11 1 _ 4w face, back, arm 
and hand
no no modified CLASI, H Significant reduction of erythema and 
scaling after treatment; significant reduc-
tion of dermal lymphocytic infiltrate and 
an important reduction of basal damage. 
ICAM-1 and VCAM-1 expression was 
reduced
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Diez et al., 
2011 (60)
4 CS 2(Lupus 
tumidus)
595 7 2 11 1 _ 4w  face and back no no modiefied CLASI, H Significant reduction of erythema and 
scaling after treatment; No epidermal 
change, no basal cel damage, decline 
of infiltrate in one patient. Significant 
decline of both ICAM-1 as VCAM-1 
5 CR 1(SCLE) 595 7 2 11 1 _ 4w face, back, arm 
and hand
no no modified CLASI, H Abscence of erythema and scaling after 
treatment. No biopsie data available after 
treatment
Granuloma faciale
Ammirati 
et al., 1999 
(62)
5 CR 1 585 5 0.45 8.0;8,5 2 2m 6y nose no no ECR, P persistent clinical eradication
Welsh et al., 
1999 (63)
5 CR 1(3 le-
sions)
585 7 0.45 6.5-7.25 9 4m nose and cheek no no ECR, P complete remission in all lesions mild epidermal 
atrophy
585 3 0.45 7.0-7.5 no no ECR, P
595 7 1.5 12.0 3 6w no no ECR, P
Elston, 2000 
(64)
5 CR 1 595 6.5-7.0 3 1m 1m face no no ECR, P complete clearing
Chatrath 
et al., 2002 
(65)
5 CR 1 595 7 3.0 9.5-12.0 3 6w 9m nose no no ECR, P significant flattening of the lesions after 
two treatments, complete clearing after 
the third
Cheung et 
al., 2004 
(66)
4 CS 4 595 7 1.0-3.0 10.0-14.0 ? 2-4m temporal, 
cheek, nose
no no ECR, P two patients achieved a significant 
cosmetic improvement; the lesions 
remained unchanged in the other two 
patients
Fikrle et al., 
2011 (67)
4 CS 4 595 7 1.5 9.0-10.0 3-8 6-8w 6m face no no ECR, P complete flattening and bleaching in 
three patients (excellent), one lesion re-
mained bright red-brown after treatment 
(very good)(local steroid if no improve-
ment after 2 sessions)
Leite et al., 
2011 (68) 
5 CR 1 585 20 5.8-8.3 5 6m scalp no no ECR, P Marked improvement
Cutaneous sarcoidosis 
Goodman 
et al., 1992 
(69)
5 CR 1 585 5 0.46 5.0-8.0 2 7m 6m nose no no ECR, P improvement of 75 % after two treat-
ments
Cliff et al., 
1999 (70)
5 CR 1 585 5 0.45 5.6-7.3 6 6w 2m nose no no ECR, P, H considerable cosmetic improvement; 
presence of non-caseating granulomas 
in dermis; paucity of upper dermal blood 
vessels
Ekbäck et al., 
2005 (71)
5 CR 1 585 ? 0.45 6.75-7.0 10 cheek no ECR, P less reddish and somewhat thinner (after 
treatment with other laser there was 
a complete healing)(twice frequenced-
double YAG laser, after 10 PDL treatments)
Holzman 
et al., 2008 
(72)
5 CR 1 595 7 0.5 7.6-7.8 3 6w 12m cheek no no ECR, P clinical remission afer 3 treatments
Roos et al., 
2009 (73)
5 CR 1 585 12 0.5 6.0 1 _ 4w back no no ECR, P slight reddening, but the lesions had 
completely resolved
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Diez et al., 
2011 (60)
4 CS 2(Lupus 
tumidus)
595 7 2 11 1 _ 4w  face and back no no modiefied CLASI, H Significant reduction of erythema and 
scaling after treatment; No epidermal 
change, no basal cel damage, decline 
of infiltrate in one patient. Significant 
decline of both ICAM-1 as VCAM-1 
5 CR 1(SCLE) 595 7 2 11 1 _ 4w face, back, arm 
and hand
no no modified CLASI, H Abscence of erythema and scaling after 
treatment. No biopsie data available after 
treatment
Granuloma faciale
Ammirati 
et al., 1999 
(62)
5 CR 1 585 5 0.45 8.0;8,5 2 2m 6y nose no no ECR, P persistent clinical eradication
Welsh et al., 
1999 (63)
5 CR 1(3 le-
sions)
585 7 0.45 6.5-7.25 9 4m nose and cheek no no ECR, P complete remission in all lesions mild epidermal 
atrophy
585 3 0.45 7.0-7.5 no no ECR, P
595 7 1.5 12.0 3 6w no no ECR, P
Elston, 2000 
(64)
5 CR 1 595 6.5-7.0 3 1m 1m face no no ECR, P complete clearing
Chatrath 
et al., 2002 
(65)
5 CR 1 595 7 3.0 9.5-12.0 3 6w 9m nose no no ECR, P significant flattening of the lesions after 
two treatments, complete clearing after 
the third
Cheung et 
al., 2004 
(66)
4 CS 4 595 7 1.0-3.0 10.0-14.0 ? 2-4m temporal, 
cheek, nose
no no ECR, P two patients achieved a significant 
cosmetic improvement; the lesions 
remained unchanged in the other two 
patients
Fikrle et al., 
2011 (67)
4 CS 4 595 7 1.5 9.0-10.0 3-8 6-8w 6m face no no ECR, P complete flattening and bleaching in 
three patients (excellent), one lesion re-
mained bright red-brown after treatment 
(very good)(local steroid if no improve-
ment after 2 sessions)
Leite et al., 
2011 (68) 
5 CR 1 585 20 5.8-8.3 5 6m scalp no no ECR, P Marked improvement
Cutaneous sarcoidosis 
Goodman 
et al., 1992 
(69)
5 CR 1 585 5 0.46 5.0-8.0 2 7m 6m nose no no ECR, P improvement of 75 % after two treat-
ments
Cliff et al., 
1999 (70)
5 CR 1 585 5 0.45 5.6-7.3 6 6w 2m nose no no ECR, P, H considerable cosmetic improvement; 
presence of non-caseating granulomas 
in dermis; paucity of upper dermal blood 
vessels
Ekbäck et al., 
2005 (71)
5 CR 1 585 ? 0.45 6.75-7.0 10 cheek no ECR, P less reddish and somewhat thinner (after 
treatment with other laser there was 
a complete healing)(twice frequenced-
double YAG laser, after 10 PDL treatments)
Holzman 
et al., 2008 
(72)
5 CR 1 595 7 0.5 7.6-7.8 3 6w 12m cheek no no ECR, P clinical remission afer 3 treatments
Roos et al., 
2009 (73)
5 CR 1 585 12 0.5 6.0 1 _ 4w back no no ECR, P slight reddening, but the lesions had 
completely resolved
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Eczematous skin lesions
Syed et al., 
2008 (76)
3b OL 12 595 7 4.0;4.5;5.0 1 _ 6w no no Eczema Severity 
Score (ESS), VAS
A significant decrease in ESS and a 
significant difference in eczema severity 
assessed by VAS
one patient 
have a super-
infection with 
C.albicans at 
the treated site
Rosacea papulopustulosa
Berg et al., 
2004 (88)
3b OL 14 (10 
completed 
the study)
585 5 0.5 5.75-7.75 2.4 (1-4) 10m face no no ECR Markedly less (n=2), slight less (n=3), 
unchanged (n=3) worsened (n=2)
Hyper-
pigmentation in 
five patients
Bernstein 
et al., 2008 
(89)
4 CS 20 (17 
completed 
the study)
595 3x10
12
40
3
17-19
6.0-7.0
4 4w 2m face no no ECR Significant overall improvement Slight pain and 
edema
Lichen sclerosis 
Rabinowitz 
et al., 1993 
(80)
5 CR 1 585 5 5.75-6.25 4 genital no no ECR very good results
Greve et al., 
1999 (81)
5 CR 1 585 7 0.3-0.45 5.3-6.0 4 4-6w 7m neck/thrunk/
arm
no no ECR, H complete clearance; no residu of LSA
Passerson 
et al., 2009 
(82)
5 CR 1 (2 le-
sions)
595 10 10.0 2 1m abdomen/
breast
methyl-
aminolevulinic 
acid in breast 
lesion
no ECR moderate effect on abdominal lesion 
(PDL), marked improvement in breast 
lesion (PDL-PDT) 
Granuloma annulare
Sniezek et 
al., 2005 
(84)
5 CR 1 585 5 0.45 6.75 3 5m; 8m 3y wrist no no ECR reduction in erythema and almost com-
plete flattening
Slinger et al., 
2008 (85)
5 CR 1 595 7 1.5 8.0 1 _ 36w thrunk/limbs no no ECR complete flattening and lighting slight transient 
hypo-
pigmentation
Jessner lymphocitic infiltration
Borges da 
Costa et al., 
2009(86)
5 CR 1 595 10 0.5 8.0 1 _ ? limbs no no ECR, H complete clearing of all lesions; regres-
sion of histological findings
Reticular erythematous mucinosis
Greve et al., 
2001 (87)
4 CS 1 585 7 0.3-0.45 5.4-6.9 5 2.8m (2-7) chest/abdomen no no ECR, H only minimal residus visible; regulary 
structured skin without acute inflamma-
tion. No significant lymphocytic infiltrates 
or mucin deposits
1 585 7 6.0 3 1m; 3m 2m inframammary no no ECR skin almost completely healed slight transient 
hypo-
pigmentation
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Eczematous skin lesions
Syed et al., 
2008 (76)
3b OL 12 595 7 4.0;4.5;5.0 1 _ 6w no no Eczema Severity 
Score (ESS), VAS
A significant decrease in ESS and a 
significant difference in eczema severity 
assessed by VAS
one patient 
have a super-
infection with 
C.albicans at 
the treated site
Rosacea papulopustulosa
Berg et al., 
2004 (88)
3b OL 14 (10 
completed 
the study)
585 5 0.5 5.75-7.75 2.4 (1-4) 10m face no no ECR Markedly less (n=2), slight less (n=3), 
unchanged (n=3) worsened (n=2)
Hyper-
pigmentation in 
five patients
Bernstein 
et al., 2008 
(89)
4 CS 20 (17 
completed 
the study)
595 3x10
12
40
3
17-19
6.0-7.0
4 4w 2m face no no ECR Significant overall improvement Slight pain and 
edema
Lichen sclerosis 
Rabinowitz 
et al., 1993 
(80)
5 CR 1 585 5 5.75-6.25 4 genital no no ECR very good results
Greve et al., 
1999 (81)
5 CR 1 585 7 0.3-0.45 5.3-6.0 4 4-6w 7m neck/thrunk/
arm
no no ECR, H complete clearance; no residu of LSA
Passerson 
et al., 2009 
(82)
5 CR 1 (2 le-
sions)
595 10 10.0 2 1m abdomen/
breast
methyl-
aminolevulinic 
acid in breast 
lesion
no ECR moderate effect on abdominal lesion 
(PDL), marked improvement in breast 
lesion (PDL-PDT) 
Granuloma annulare
Sniezek et 
al., 2005 
(84)
5 CR 1 585 5 0.45 6.75 3 5m; 8m 3y wrist no no ECR reduction in erythema and almost com-
plete flattening
Slinger et al., 
2008 (85)
5 CR 1 595 7 1.5 8.0 1 _ 36w thrunk/limbs no no ECR complete flattening and lighting slight transient 
hypo-
pigmentation
Jessner lymphocitic infiltration
Borges da 
Costa et al., 
2009(86)
5 CR 1 595 10 0.5 8.0 1 _ ? limbs no no ECR, H complete clearing of all lesions; regres-
sion of histological findings
Reticular erythematous mucinosis
Greve et al., 
2001 (87)
4 CS 1 585 7 0.3-0.45 5.4-6.9 5 2.8m (2-7) chest/abdomen no no ECR, H only minimal residus visible; regulary 
structured skin without acute inflamma-
tion. No significant lymphocytic infiltrates 
or mucin deposits
1 585 7 6.0 3 1m; 3m 2m inframammary no no ECR skin almost completely healed slight transient 
hypo-
pigmentation
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General discussion and conclusions
In the general discussion and conclusions of the thesis, we will revisit the aims as 
defined in the introduction and formulate conclusions, based on the corresponding 
chapters of the thesis and relevant literature. 
Aim 1: To investigate the efficacy of a vascular laser in spider naevi 
Vascular lasers are considered the gold standard for the treatment of many vascular 
indications such as port-wine stains, hemangiomas and facial telangiectasias.1,2 
It is an effective method, however possible side effects restrict its use: pain, crust 
formation and pigmentary changes.3,4 For smaller vascular lesions electrocoagulation 
(EC) is preferred by many dermatologists, as this method is easily available in daily 
practice and can be instantly performed in every out-patient department of the 
dermatologist and last but not least is well tolerated by the patients.
In chapter 2.1 we compared the efficacy and safety of the vascular KTP laser with electro-
coagulation in the treatment of spider nevi (SN). No significant difference between 
these methods was observed, although there was a tendency toward significance with 
respect to the clinical outcomes in favor of the KTP laser, both by patient assessments 
as by physician assessments. Pain was reported for both treatments, although for 
the KTP laser this was significantly less than for EC treatment. This can be explained 
by the lesser amount of tissue damage caused by laser treatment and the presence 
of a water cooled sapphire laser chill tip, causing some local anesthesia. Side effects 
such as hypopigmentation, hyperpigmentation or scar formation were not observed, 
making both KTP and EC suitable treatment options.
Conclusion: The vascular KTP laser cannot be regarded as superior to 
electrocoagulation for the treatment of spider nevi. If KTP is available at the 
treatment centre, this option may meet a higher patient satisfaction.
Aim 2: To explore the potential value of pulsed dye laser in solitary 
recalcitrant lesions of plaque psoriasis and CDLE
Studies in recalcitrant psoriasis
In psoriasis the presence of dilated, elongated and increased prominent superficial 
capillaries in the dermis can facilitate an increased influx of T-cells and other 
immunocytes into the skin, maintaining the chronic inflammatory reaction.5,6 So 
far, the exact mechanisms behind the maintenance of the psoriatic inflammation 
remains unclear. Before the experiments of this thesis, several groups explored the 
potential value of PDL in psoriasis.7-12 Variable results have been reported ranging 
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from no improvement at all to complete remission. The methods of pulsed dye laser 
(PDL) treatment were at variance with respect to fluence and spot size and pulse 
duration. Therefore, we set out a new study with a direct comparison of PDL with 
a commonly used therapeutic and we monitored the responses to treatment using 
clinical and immunohistological methods, in order to explore the potential and the 
mode of action of PDL in the treatment of psoriasis.
In chapter 3.1 we evaluated the clinical efficacy and tolerability of PDL treatment 
compared to an active comparator: calcipotriol 50 μg/g and betamethasone 
dipropionate 0.5 mg/g ointment (CB) (Daivobet®/Dovobet®). After a dose finding a 
consistent schedule with fixed spotsizes and fluences and pulse duration was adhered 
to. The pulsed dye laser therapy showed an efficacy similar to the CB during the first 4 
weeks of active treatment. However, PDL showed substantially and significantly higher 
efficacy after an additional 8 week follow-up. We have to reconcile that patients in this 
study had a history of refractory psoriasis not responding to topical therapies. Although 
PDL was well tolerated by most patients, one out of eight patients had to terminate 
the study early due to pain, which has been described as a possible side effect of 
this therapy. Another adverse event is the occurrence of pigmentary changes after 
treatment. Indeed, residual hyperpigmentation was observed in 4 out of 8 patients.
Conclusion: PDL treatment may be considered for the treatment of solitary recalcitrant 
psoriatic plaques, when other topical therapies have failed.
In chapter 3.2 the immunohistological changes of PDL treatment were compared 
and contrasted with CB treatment. Histological studies to assess the effect of PDL 
have previously been performed, examining mostly the diseased dermal vasculature 
and angiogenesis. In one study, the mean microvessel count, using CD31 as 
marker, decreased significantly during PDL treatment and showed a strong positive 
correlation with the decrease of clinical severity.13. In another study, using indicators 
of angiogenesis, including endothelial surface area, endothelial cell proliferation 
and endothelial cell expression of adhesion molecules, showed that PDL affected 
the superficial capillary bed, causing a reduction in both endothelial surface area 
and endothelial cell proliferation in the superficial dermis.14 Indeed, dermal capillary 
changes might be a permissive factor in the facilitation of traffic of pathogenic T-cells 
into the skin and in perpetuation of the psoriatic process. Therefore, we studied the 
dynamics of activated (CD2, CD25) and memory effector (CD45RO) T cells of the 
T-helper (CD4) and cytotoxic (CD8) subset and epidermal markers for proliferation 
(Ki67) and differentiation (K10) during PDL treatment in comparison with CB. Twelve 
weeks after initiation of PDL a significant decline of activated and memory effector 
T-helper cells in the dermis, cytotoxic T-cells in the epidermis and normalization of 
epidermal proliferation and keratinization in epidermal and dermal T-cell subsets was 
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seen, in contrast to the more modest changes following treatment with CB. We have 
to reconcile that these observations were made in chronic recalcitrant plaques. In 
the pathogenesis of psoriasis, evidence is accumulating that microvascular changes 
occur well before overt T-cell infiltration and epidermal hyperplasia in the process of 
formation of a psoriatic plaque. Therefore, it may be hypothesized that destroying 
the diseased capillaries helps preventing T-cells to extravasate into the skin. This 
might be a reason for long-standing therapeutic effect of PDL in psoriasis and the 
observed prolonged immuno-histochemical and clinical improvements.
Conclusion: Memory effector T-helper cells and cytotoxic T cells, as well as markers 
for epidermal proliferation and keratinization in recalcitrant psoriatic plaques are 
reduced by PDL treatment well beyond the effect of CB treatment. 
Studies in recalcitrant CDLE
Untreated CDLE can lead to disfigurement in openly visible areas such as the face, scalp, 
neck and hands, resulting in major psychologic stress.15,16 When current treatment 
options lack efficacy or adverse events are experienced, PDL treatment may be tried. 
Indeed, efficacy of PDL treatment has been claimed in several reports.17-20 However 
the evidence for these claims is limited so far: 
In none of these studies validated scoring methods were used.I. 
Different laser parameters, different treatment schedules, and even different II. 
laser devices complicate the interpretation of these studies.
In chapter 3.3 we described the development of a new scoring system for CDLE which 
focuses on one single representative target lesion: the DLE-skin score (DLE-SS) and 
the DLE-photo score (DLE-PS). The first one is the sum of erythema(E), induration(I), 
scaling(S) and atrophy(A),and the latter is the sum of erythema(E), scaling(S) and 
atrophy(A), because induration cannot be measured from a picture. Both DLE-SS 
and DLE-PS proved reliable methods in the assessment of a single CDLE lesion. The 
inter-observer variability of the DLE-PS was low, even lower than the intra-observer 
variability of the DLE-SS (2.0 vs 6.0). We also found a high correlation between the 
DLE-SS and DLE-PS. So, in conclusion, both DLE-SS and DLE-PS are reliable and easy-
to-use methods to score disease activity in CDLE patients. We prefer, however, the 
DLE-SS because this method also measures induration, which is a key feature in 
disease activity. 
Conclusion: DLE-SS and DLE-PS, as developed by our group, are reliable and easy-to-
use methods to score one single lesion in CDLE patients (chapter 3.3). These scores 
do not provide a differentiation between disease activity and damage.
During the above mentioned studies a new scoring system was published: the 
cutaneous lupus erythematosus disease area and severity index (CLASI) which is 
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a validated instrument to measure disease severity and improvement in CDLE.21 
This score comprises the components erythema, induration, scaling and atrophy of 
the DLE-PS and DLE-SS. But it extends this score as it records and values the areas 
of involvement, based on an assessment of the actual sites of involvement and it 
differentiates between “disease activity” and “disease damage”. The latter is of major 
importance in the evaluation of the effect of treatments. The CLASI is a good scoring 
system to investigate the value of a treatment for the management of the patient 
with DLE as disease activity and damage are scored separately. It was, however not 
developed to score one single target lesion.
In chapter 3.4 we evaluated one single target lesion in 12 patients with recalcitrant 
CDLE during treatment with the PDL, using standardized laser parameters and 
treatment intervals. Instead of using the developed scoring system (3.3) we used the 
CLASI as this score differentiates between disease activity and damage. As we only 
assessed one target lesion in stead of the whole body, we decided to refer to this 
scoring system as the limited CLASI. We evaluated whether the CLASI scoring method 
was applicable to one single lesion. CLASI (disease-activity) comprises erythema, 
induration and scaling. CLASI (disease-damage) comprises dyspigmentation, 
scarring, and atrophy. The CLASI (disease-activity) and the CLASI (disease-damage) 
were calculated for each target lesion before and during laser treatment. At the same 
time clinical pictures of the target lesion were taken before and after treatment, and 
evaluated by two independent dermatologists using the CLASI. A significant decline 
in the limited CLASI (disease-activity) was observed after 6 weeks, after 12 weeks, 
and at follow-up. Baseline limited CLASI (disease-activity) was 4.4 ± 0.2 (mean 
± SEM), reaching 1.3 ± 0.3 after follow-up (p <.0001). The limited CLASI (disease-
damage) did not show any significant change during or after therapy. Therefore, it 
is important to differentiate between activity scores and damage scores also in the 
application of DLE-SS and DLE-PS. The observed clinical improvement was confirmed 
by two independent observers by clinical assessment of photographs (r =0.87 and 
r=.89; both p <.05). The two photograph observers intercorrelated well with r =0.96. 
Patients experienced minimal pain during treatment and only one patient developed 
slight hyperpigmentation. The overall cosmetic result was fair.
Conclusions:
The use of the CLASI scoring method was extended for the follow up of severity I. 
of one single CDLE lesion: the limited CLASI.
Limited CLASI (disease-activity) is an assessment tool which permits II. 
quantification of relevant clinical improvement in recalcitrant CDLE.
In the present study, limited CLASI was not superior to DLE SS, as disease III. 
damage did not change during treatment.
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PDL treatment is an effective and safe therapy for patients with refractory CDLE, IV. 
and may be considered for treatment when topical and/or systemic therapies 
have failed or are contraindicated.
Aim 3: To position pulsed dye laser therapy in inflammatory skin diseases 
based on a systematic literature review 
PDL has been used in various inflammatory skin conditions. Many reports are available 
and the outcomes are at variance. The methodology of PDL in various reports is often 
different. Therefore, we felt that it was important to get a clear view on the actually 
available evidence on the treatment of PDL in inflammatory skin diseases.
In chapter 4.1 all publications of the treatment of inflammatory skin diseases with 
the pulsed dye laser from Januari 1992 till August 2011 were collected, and after 
determining the level of evidence according to the Oxford Center for Evidence-
based Medicine Levels of Evidence, a recommendation grade was given for all found 
inflammatory skin disease. Literature concerning treatment efficacy and safety of 
pulsed dye laser for inflammatory skin diseases was diverse. Overall, most studies22 
have shown limitations in small patient numbers, inconsistent treatment parameters, 
non-validated treatment parameters and a relatively short follow up period. Large 
randomized controlled trials with consistent laser parameters, validated outcome 
measures and long follow-up period were lacking. 
Psoriasis was the most frequently investigated inflammatory skin disease22. All 
studies described the treatment of localized psoriasis, which mostly concerned 
chronic, stable plaque psoriasis, sometimes explicitly described as recalcitrant, not 
responding to conventional therapy such as potent topical steroids, UVB, PUVA and 
tar. The results of the individual studies were at variance. Despite the frequency of 
this skin disease, no large randomized controlled trials on PDL for psoriasis were 
identified. Practically, PDL treatment should be restricted to a few psoriasis plaque 
lesions which are resistant to conventional therapy. Taking into consideration the 
evidence for superior efficacy in psoriasis as compared to topical treatment (present 
thesis) and various promising results as described in the review, according to our 
opinion, PDL should be considered for solitary recalcitrant psoriatic lesions.
Two large randomized controlled trials were preformed for acne treatment with 
PDL.22 The results of these studies were at variance, which could be explained by 
different laser parameters which were used and other treatment regimens. PDL 
treatment for acne in other studies showed good results compared to a control side 
and compared to conventional treatments. Despite these positive finding it is still 
unclear, whether PDL treatment for acne will become a standard treatment in the 
future. No large intra-patient, left right comparative studies were done with PDL 
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treatment in comparison with other well established, easy accessible treatments. 
Therefore we cannot conclude that PDL has an added value to conventional forms of 
therapy. One could hypothesize that it can be an alternative when topical therapies 
have failed or are contraindicated, before starting systemic therapy. However, so far, 
a study showing the value of PDL in recalcitrant acne is not available to the best of 
our knowledge.
Evidence for other in the review mentioned inflammatory skin diseases (SLE, 
CDLE, SCLE, granuloma faciale, cutaneous sarcoidosis, chronic eczema, lichen 
sclerosis, granuloma annulare, Jessner lymphocytic infiltration of the skin, reticular 
erythematous mucinosis and papulopustular rosacea) is of a low level, i.e. grade C 
and D. While the incidence of these skin diseases, except for chronic eczema, is quite 
low, it is unlikely that large randomized trials will be performed in the near future 
to position the PDL for these skin diseases. Despite the low recommendation level, 
we recommend to consider treating recalcitrant lesions in these diseases with PDL 
as a last resort treatment, when topical and/or systemic therapies have failed or are 
contraindicated. In this respect we have to realize that unmet medical need in these 
patients can be substantial as these treatment resistant lesions are often located in 
the facial area and chest.
Conclusions:
Evidence grade B is allocated for PDL treatment of both localized psoriasis and I. 
acne vulgaris.
PDL has an added value in the treatment of recalcitrant psoriasis (present II. 
thesis).
For all other described inflammatory skin diseases PDL seems to be promising, III. 
although the level of recommendation did not exceed level C.
Controlled studies, taking into consideration the long-term course of the IV. 
disease in large groups of patients are needed.
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Overall aim:
At the end of this thesis we revisit the overall aim: To explore the value of pulsed dye 
laser in the treatment of inflammatory skin diseases, inspired by the well established 
effect in vascular lesions and the evidence of involvement of the microvasculature in 
inflammatory dermatoses.
Indeed in classical vascular lesions, PDL has a well established position. But is it 
the panacea which makes this treatment first choice in all situations? In a common 
condition such as spider naevi, clearly, treatment by electrocoagulation remains to 
be an excellent first choice. 
Reviewing the literature, one can conclude that our current understanding of 
vascular involvement in inflammation has expanded and several new leads to target 
the microvasculature in these diseases are promising research targets.
Validated scoring systems are crucial in order to be able to assess the value of 
treatments. In this thesis we have made a contribution to the development of new 
scoring systems in DLE.
Our investigation on the potential value of vascular lasers in inflammatory skin 
diseases comprised exploratory studies in solitary recalcitrant psoriasis plaques and 
recalcitrant DLE lesions and a systematic literature review. In both treatment resistant 
conditions, this thesis suggests that PDL is a valuable treatment option well beyond 
the efficacy of current anti-inflammatory treatments. 
The evidence on efficacy and cost effectiveness of PDL in inflammatory skin diseases 
remains to be studied further, in order to position vascular lesions in S3 guidelines for 
the treatment of these diseases.
This thesis lends support for the development of new treatment options targeted on 
the microvasculature of inflammatory skin diseases.
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Summary
The overall aim of the thesis is to explore the value of pulsed dye laser in the treatment 
of inflammatory skin diseases, inspired by the well established effect in vascular 
lesions and the evidence of involvement of the microvasculature in inflammatory 
dermatoses.
In classical vascular lesions, PDL has a well-established position. But is it the panacea 
that makes this treatment first choice in all vascular skin lesions? In chapter 2.1 a 
comparative study between KTP laser and electrocoagulation was carried out. No 
significant difference between these methods was observed, although there was a 
tendency toward significance with respect to the clinical outcomes in favor of the 
KTP laser. Pain was reported for both treatments, although for the KTP laser this was 
significantly less than for EC treatment. KTP laser cannot be regarded as superior to 
electrocoagulation. If KTP is available at the treatment center, this option may meet 
a higher patient satisfaction.
In the treatment of inflammatory skin diseases an important unmet medical need 
exists for recalcitrant treatment resistant lesions. The question was addressed 
whether pulsed dye laser (PDL), by targeting the endothelial changes in these 
recalcitrant inflammatory lesions, might provide a unique last resort treatment for 
these therapy resistant lesions. 
We explored the potential value of pulsed dye laser in inflammatory skin diseases: 
In chapters 3.1 and 3.2 our investigations in solitary recalcitrant psoriatic lesions 
have been described.
The clinical efficacy and tolerability of PDL treatment was compared with a first line 
topical treatment: calcipotriol 50 μg/g and betamethasone propionate 0.5 mg/g 
ointment (CB) (Daivobet®/Dovobet®). In view of its superior efficacy, PDL treatment 
may be considered for the treatment of localized, recalcitrant plaque psoriasis, when 
other topical therapies have failed. 
The immune histological changes of PDL treatment were compared and contrasted 
with CB treatment: memory effector T-helper cells and cytotoxic T cells, as well as 
markers for epidermal proliferation and keratinization in recalcitrant psoriatic plaques 
are reduced by PDL treatment well beyond the effect of CB treatment.
In chapter 3.3 and 3.4 the investigations in solitary recalcitrant CDLE lesions have 
been described.
Before starting therapeutic evaluations a new scoring system for CDLE was developed 
and evaluated by our group, which focuses on one single representative target lesion: 
the DLE-skin score (DLE-SS) and the DLE-photo score (DLE-PS). The first one is the sum 
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of erythema (E), induration (I), scaling (S) and atrophy (A), and the latter is the sum 
of erythema(E), scaling(S) and atrophy(A). DLE-SS and DLE-PS are reliable and easy-
to-use methods to score one single lesion in CDLE patients. The score is comparable 
with the SUM score in psoriasis. This score is not providing a differentiation between 
“disease activity” and “disease damage” and it does not take into account the various 
localizations. During our studies another group published a new scoring system: The 
Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). CLASI 
comprises the key elements E, I, S and E of the DLE-SS and DLE-PS We used for our 
studies on the efficacy of PDL in CDLE the CLASI as it differentiates between disease 
activity and disease damage. As we did our studies on solitary lesions we designated 
the scoring system “limited CLASI”. PDL treatment proved to be an effective and safe 
therapy for patients with refractory CDLE, and may be considered for treatment 
when topical and/or systemic therapies have failed or are contraindicated.
PDL has been used in various inflammatory skin conditions. Many reports are available 
and the outcomes are at variance. In chapter 4.1 a systematic literature study has 
been described, analyzing all publications of the treatment of inflammatory skin 
diseases with the pulsed dye laser from January 1992 till August 2011. The following 
conclusions were drawn:
Evidence grade B is allocated for PDL treatment of both localized psoriasis and  -
acne vulgaris. 
PDL has an added value in the treatment of recalcitrant psoriasis (present  -
thesis).
For various inflammatory skin diseases PDL seems to be promising, although the  -
level of recommendation did not exceed level C.
Controlled studies, taking into consideration the long-term course of the disease  -
large groups of patients are needed.
In solitary recalcitrant inflammatory skin diseases, PDL has proven to provide a valuable 
treatment option beyond the efficacy of current anti-inflammatory treatments. The 
evidence on efficacy and cost effectiveness of PDL in these diseases remains to be 
studied further, in order to position PDL in S3 guidelines for the treatment of these 
diseases. 
This thesis lends support for the development of new treatment options targeted on 
the microvasculature of inflammatory skin diseases.
Chapter 6
Summary & Samenvatting
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Samenvatting
Het doel van dit proefschrift is om de waarde van de pulsed dye laser te onderzoeken 
bij de behandeling van inflammatoire huidaandoeningen, geïnspireerd door het 
reeds bewezen effect bij vasculaire afwijkingen en het bewijs van betrokkenheid van 
microvasculatuur bij inflammatoire dermatosen.
De pulsed dye laser heeft inmiddels een belangrijke positie verworven bij de 
behandeling van klassieke vasculaire afwijkingen. Maar is dit de panacee, waardoor 
deze behandeling de eerste keus is voor alle vasculaire afwijkingen? In hoofdstuk 2.1 
werd een vergelijkend onderzoek uitgevoerd tussen de KTP laser en electrocoagulatie. 
Er werd geen significant verschil gezien tussen deze beide methoden, alhoewel 
er een tendens was tot significantie in het voordeel van de KTP laser. Bij beide 
behandelingen werd pijn gerapporteerd, alhoewel dit voor de behandeling met de 
KTP laser significant lager lag, dan voor electrocoagulatie. De KTP laser kon niet als 
superieur worden beschouwd ten opzichte van electrocoagulatie. Indien men in de 
praktijk de beschikking heeft tot de KTP laser, dan zou behandeling hiermee tot een 
hogere patiënt tevredenheid leiden.
Bij de behandeling van inflammatoire huidaandoeningen bestaat er een grote 
behoefte voor de behandeling van recalcitrante, therapieresistente afwijkingen. 
De vraag die gesteld werd was of pulsed dye laser, door zijn directe werking op 
endotheliale veranderingen in deze recalcitrante inflammatoire laesies, een unieke 
laatste behandelkans zou kunnen verschaffen voor de behandeling van deze 
therapieresistente huidafwijkingen.
We onderzochten de potentiële waarde van de pulsed dye laser (PDL) bij inflammatoire 
huidziekten:
In de hoofdstukken 3.1 en 3.2 worden onze onderzoeken bij solitaire recalcitrante 
psoriasis beschreven.
De klinische effectiviteit en tolerabiliteit van de PDL behandeling werd vergeleken 
met een eerste lijns topicale behandeling: calcipotriol 50μg/g en betamethasone 
propionate 0.5 mg/g ointment (CB) (Daivobet®/Dovobet®). Gelet op zijn superieure 
effectiviteit, kan PDL behandeling worden overwogen voor de behandeling van 
gelokaliseerde, recalcitrante plaque psoriasis, nadat andere topicale behandelingen 
onvoldoende werkzaam zijn gebleken.
De immunohistologische veranderingen na PDL behandeling werden vergeleken en 
afgezet tegen CB behandeling: Afwijkende bevindingen in de recalcitrante psoriasis 
plaques met betrekking tot effector T-helper geheugen cellen en cytotoxische T cellen, 
evenals met betrekking tot markers voor epidermale proliferatie en keratinisatie 
worden minder na PDL behandeling, meer dan het effect van CB behandeling.
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In de hoofdstukken 3.3 en 3.4 worden onderzoeken naar solitaire recalcitante 
chronische discoide lupus erythematodes (CDLE) laesies en de meetmethoden 
hiervan beschreven.
Nog voor de aanvang van therapeutische evaluaties, werd een nieuw scoringssysteem 
voor CDLE ontwikkeld en geëvalueerd door onze groep, met de focus op een enkele 
“test” laesie: de DLE-skin score (DLE-SS) en DLE-photo score (DLE-PS). De eerste 
is een optelsom van erytheem (E), induratie (I) schilfering (S) en atrofie (A) en de 
laatste is de optelsom van erytheem (E), schilfering (S) en atrofie (A). DLE-SS en DLE-
PS zijn betrouwbare en gemakkelijk bruikbare methoden om een enkele laesie in 
CDLE patiënten te scoren. De score is vergelijkbaar met de SUM score in psoriasis. 
Deze score voorziet niet in een holistische benadering, noch in de differentiatie 
tussen “ziekteactiviteit” en “ziekteschade” en voorziet niet een score voor ernst 
met betrekking tot verscheidene lokalisaties. Gedurende onze studies werd een 
nieuw scoringssysteem door een andere groep gepubliceerd: “The cutaneous lupus 
erythematodes disease and severity index” (CLASI). CLASI bevat de hoofdelementen 
E, I, S en E van de DLE-SS en DLE-PS. Het CLASI scoringssysteem geniet de voorkeur 
om de behandelwaarde te onderzoeken voor de behandeling van de patiënt met 
CDLE, daar het differentieert tussen ziekte activiteit en ziekte schade. Wij hebben 
de CLASI in studie naar de effectiviteit van de PDL voor CDLE gebruikt, en konden 
aantonen dat deze scoringsmethode, in een aangepaste vorm (limited CLASI) ook 
toepasbaar kon zijn op een solitaire laesie. PDL bleek een effectieve en veilige manier 
te zijn voor de behandeling van hardnekkige CDLE laesie, en kan overwogen worden 
indien topische en/of systemische therapie tekort schiet of gecontra-indiceerd is.
PDL werd in verscheidene inflammatoire huidziekten toegepast. Veel rapporten 
hieromtrent zijn beschikbaar en de uitkomsten zijn wisselend. In hoofdstuk 4.1 
word een systematische literatuurstudie beschreven, waarin alle publicaties van de 
behandeling van inflammatoire huidziekten tussen januari 1992 en augustus 2011 
worden beschreven. De volgende conclusie konden hieruit getrokken worden:
Bewijskracht graad B is vastgesteld voor PDL behandeling van zowel gelokaliseerde  -
psoriasis als van acne vulgaris.
PDL heeft een toegevoegde waarde in de behandeling van recalcitrante psoriasis  -
(huidig proefschrift).
Voor diverse inflammatoire huidziekten lijkt PDL veelbelovend te zijn, alhoewel  -
het niveau van aanbeveling level C niet ontstijgt.
Gecontroleerde studies, met inachtneming van het lange-termijns beloop van de  -
aandoening in grote patiëntengroepen zijn nodig.
Bij solitaire recalcitrante inflammatoire huidziekten, heeft PDL bewezen een 
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waardevolle behandeloptie te zijn naast de doeltreffendheid van huidige anti-
inflammatoire behandelingen. Het bewijs van efficiëntie en kosten effectiviteit van 
PDL in deze aandoening zou nog verder onderzocht moeten worden, voordat de PDL 
kan worden gepositioneerd in de S3 richtlijnen van deze aandoeningen.
Dit proefschrift ondersteunt de ontwikkeling van nieuwe behandelingen gericht op 
de microvasculatuur van inflammatoire huidziekten.
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